Anti-C. difficile cell surface protein Polyclonal Antibody

Gravina, Alessia, et al. "Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression." Nature biotechnology 41.5 (2023): 717-727.

The study investigates the protection of cell therapeutics from antibody-mediated killing through the overexpression of CD64. This approach enhances the survival and efficacy of allogeneic cell therapeutics used in cancer therapy and regenerative medicine. The research demonstrates that engineered cells overexpressing CD64 can effectively evade antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are primary mechanisms of antibody-mediated rejection.
At Creative Biolabs, we provided several essential reagents for this research. These included the humanized anti-MICA IgG1 antibody (Cat#: TAB-0799CL), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0089WJ), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0014JF), and the hypusine antibody (Cat#: HPAB-0440-YJ). Our products were crucial for the experiments involving antibody-mediated killing assays, enabling the detailed examination of how engineered cells can evade immune detection and destruction. This study highlights the potential of CD64 overexpression to enhance the viability of cell-based therapies, underscoring our commitment to supporting advanced research and innovative therapeutic solutions.

Wang, Lixue, et al. "Bioinspired engineering of fusogen and targeting moiety equipped nanovesicles." Nature Communications 14.1 (2023): 3366.

This study focuses on the bioinspired engineering of fusogen and targeting moiety equipped nanovesicles (eFT-CNVs) to enhance drug delivery efficiency. The researchers developed eFT-CNVs by mechanically extruding genetically modified donor cells to produce high-yield and consistent nanovesicles. These engineered vesicles co-express a fusogen derived from the Sindbis virus and an anti-GPC3 single-chain variable fragment (scFv), enabling them to selectively bind to GPC3-overexpressing cancer cells and facilitate efficient cytosolic drug delivery through membrane fusion. The study demonstrated that eFT-CNVs significantly improve the treatment efficacy of drugs targeting cytosolic components, suggesting that these nanovesicles hold promise for advancing nanomedicine and precision medicine.
Creative Biolabs contributed to this research by providing the anti-HA antibody Fab fragment (Cat# FAMAB-0254-YC-F(E)). This antibody was essential for estimating the concentration of fusogen on eFT-CNVs, which was crucial for evaluating the efficiency of membrane fusion and drug delivery. By enabling precise quantification of fusogen molecules, the anti-HA antibody from Creative Biolabs supported the researchers in optimizing the design and functionality of the bioengineered nanovesicles, thereby facilitating the study's goal of enhancing targeted drug delivery systems.

Xie, Shiwei, et al. "Recombinant human bone morphogenetic protein 2 and 7 inhibit the degeneration of intervertebral discs by blocking the Puma-dependent apoptotic signaling." International journal of biological sciences 17.9 (2021): 2367.

This study investigates the protective effects of recombinant human bone morphogenetic proteins (rhBMP2 and rhBMP7) on intervertebral disc degeneration (IDD). The researchers found that BMP levels were significantly decreased in IDD patients, leading to impaired BMP/Smad signaling and the induction of Puma-dependent apoptosis. The study demonstrated that supplementation with rhBMP2 and rhBMP7 could decrease the expression of pro-apoptotic Puma and its downstream molecules, thereby inhibiting apoptosis in nucleus pulposus (NP) cells. In vivo experiments further confirmed that administration of rhBMPs in aged rats significantly suppressed IDD progression.
Creative Biolabs provided the formaldehyde (Cat# Glyco-032CL) used in the chromatin immunoprecipitation (ChIP) assay to cross-link DNA-protein complexes. This reagent was crucial for the successful execution of the ChIP assay, enabling the researchers to determine the occupancy of transcription factors on the PUMA promoter. The precise performance of the formaldehyde from Creative Biolabs ensured accurate and reproducible results, supporting the study's exploration of the molecular mechanisms underlying IDD and the therapeutic potential of rhBMPs.

Qian, Qian, et al. "Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway." Journal of Gastrointestinal Oncology 11.2 (2020): 337.

The study explores the relationship between Interleukin 10 (IL-10) and Programmed Death-Ligand 1 (PD-L1) in esophageal carcinoma (ESCA) tissues, examining how IL-10 regulates PD-L1 expression via the Met signaling pathway. The research involved 100 ESCA patients who underwent surgery with preoperative therapy. The study utilized immunohistochemical staining, qRT-PCR, Western blots, and ELISA to measure PD-L1, IL-10, and Met expression levels in cancer, adjacent, and normal tissues. The findings revealed that high levels of PD-L1 and IL-10 were associated with poor prognosis in ESCA patients. The study demonstrated that IL-10 reduces PD-L1 expression in esophageal squamous cell lines through the Met signaling pathway and that the combination of crizotinib and IL-10 effectively inhibits the proliferation, invasion, and migration of these cell lines.
Creative Biolabs contributed significantly to this research by providing the anti-IL-10 antibody used in the cell culture experiments. This antibody (CAT#: HPAB-0224CQ) was crucial for investigating the modulation of PD-L1 expression by IL-10 in esophageal squamous carcinoma cells. The provision of this antibody enabled the researchers to conduct detailed experiments on the interplay between IL-10 and PD-L1, which was essential for understanding the potential therapeutic strategies for ESCA involving immune modulation.

Shen, Jingjing, et al. "Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment." Science advances 9.4 (2023): eabq3104.

This study focuses on developing an innovative delivery system for macromolecular ophthalmic drugs to treat ocular fundus diseases using eyedrop formulations. Traditional treatments like intravitreal injections present risks such as infections and retinal detachment. This research introduces a penetrating carrier based on fluorocarbon-modified chitosan (FCS), which can self-assemble with proteins to form nanocomplexes. These nanocomplexes effectively traverse ocular barriers to reach the posterior eye segments, demonstrating superior therapeutic responses in mouse models of choroidal melanoma and choroidal neovascularization compared to conventional methods. The FCS/anti-PDL1 and FCS/anti-VEGFA eyedrops induced stronger antitumor immune responses and inhibited vascular proliferation, respectively, showcasing the potential for at-home treatment of various eye diseases.
In this study, Creative Biolabs provided crucial therapeutic antibodies that were integral to the research. Specifically, they supplied anti-VEGFA (Cat#: HPAB-0330CQ), which was used in the formulation of FCS/anti-VEGFA nanocomplexes for treating choroidal neovascularization. This antibody played a pivotal role in achieving comparable therapeutic effects to intravitreal injections, thus validating the efficacy of the new delivery system. The contributions of Creative Biolabs significantly advanced the study, highlighting the potential for noninvasive, effective treatment options for ocular diseases.

Gravina, Alessia, et al. "Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression." Nature biotechnology 41.5 (2023): 717-727.

The study investigates the protection of cell therapeutics from antibody-mediated killing through the overexpression of CD64. This approach enhances the survival and efficacy of allogeneic cell therapeutics used in cancer therapy and regenerative medicine. The research demonstrates that engineered cells overexpressing CD64 can effectively evade antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are primary mechanisms of antibody-mediated rejection.
At Creative Biolabs, we provided several essential reagents for this research. These included the humanized anti-MICA IgG1 antibody (Cat#: TAB-0799CL), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0089WJ), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0014JF), and the hypusine antibody (Cat#: HPAB-0440-YJ). Our products were crucial for the experiments involving antibody-mediated killing assays, enabling the detailed examination of how engineered cells can evade immune detection and destruction. This study highlights the potential of CD64 overexpression to enhance the viability of cell-based therapies, underscoring our commitment to supporting advanced research and innovative therapeutic solutions.

Sautto, Giuseppe A., et al. "A computationally optimized broadly reactive antigen subtype-specific influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin." The Journal of Immunology 204.2 (2020): 375-385.

This study focuses on the development of a computationally optimized broadly reactive antigen (COBRA) subtype-specific influenza vaccine strategy. The research aimed to generate and evaluate the efficacy of a COBRA-based hemagglutinin (HA) immunogen in eliciting broadly neutralizing antibodies against multiple H1N1 influenza viral strains. Through the immunization of mice with the COBRA HA antigen, the study successfully identified monoclonal antibodies (mAbs) with broad hemagglutination inhibition (HAI) activity, capable of recognizing and neutralizing a diverse array of H1N1 strains, both seasonal and pandemic. The findings demonstrated that the COBRA HA vaccine elicited a robust and wide-ranging immune response, providing insights into the design of a more universally protective influenza vaccine.
Creative Biolabs contributed to this study by providing several key monoclonal antibodies used for binding and functional studies, including HA stem-directed human mAbs CR6261, FI6 (Cat#: HPAB-M0100-YC), and F10. These antibodies were essential in the characterization of the immune response elicited by the COBRA HA vaccine. Specifically, they were used to evaluate the breadth and specificity of the antibody response, helping to identify mAbs with the desired broad reactivity and neutralizing capabilities. The reliable performance of these mAbs ensured accurate and reproducible results, supporting the study's goal of advancing the development of a next-generation influenza vaccine.

Abreu, Rodrigo B., et al. "IgA responses following recurrent influenza virus vaccination." Frontiers in immunology 11 (2020): 528797.

This study investigates the IgA responses following recurrent influenza virus vaccination. Researchers administered the split inactivated influenza vaccine to young adults (18-34 years old) and elderly (65-85 years old) subjects for three consecutive seasons. They then profiled the serological IgA and IgG responses. The study aimed to understand the correlation between vaccine-induced IgA antibody titers and traditional immunological endpoints. The results showed that both young and elderly subjects developed specific IgA responses to the influenza vaccine, highlighting IgA as an important immune correlate during influenza vaccination.
Creative Biolabs contributed to this study by providing the stem-directed monoclonal antibody CR6261 and FI6 (Cat#: HPAB-M0100-YC). These antibodies were used to validate the correct stem conformation of the chimeric HA protein through enzyme-linked immunosorbent assay (ELISA). The involvement of these antibodies was crucial in ensuring the accuracy and reliability of the HA protein structure, thereby supporting the study's evaluation of the serological IgA response to the influenza vaccine.

Pellom, Samuel T., et al. "Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009." JCI insight 6.7 (2021).

The study investigates the efficacy of the recombinant gorilla adenovirus HPV therapeutic vaccine, PRGN-2009, targeting HPV-associated malignancies. PRGN-2009 is designed to express multiple cytotoxic T cell epitopes from the HPV 16/18 E6 and E7 proteins, aiming to stimulate strong HPV-specific immune responses. The vaccine was tested in both humanized and syngeneic mouse models bearing HPV16+ tumors. Results showed significant tumor volume reduction and increased infiltration of multifunctional CD8+ and CD4+ T cells in the tumor microenvironment. These findings suggest PRGN-2009's potential as an effective therapeutic vaccine for HPV-associated cancers.
Creative Biolabs provided crucial reagents for this study, including the mouse HPV16 E7 tetramer (CAT#: MHC-LC291). This tetramer was essential for evaluating antigen-specific CD8+ T cell responses in the tumor microenvironment. By facilitating the detailed assessment of immune cell infiltration and functionality, Creative Biolabs' products enabled a comprehensive analysis of PRGN-2009's immunogenicity and antitumor efficacy.

Banerjee, Anirban, et al. "Retargeting IL-2 signaling to NKG2D-expressing tumor-infiltrating leukocytes improves adoptive transfer immunotherapy." The Journal of Immunology 207.1 (2021): 333-343.

This study explores the use of a novel IL-2 mutant retargeted to NKG2D for the adoptive transfer of tumor-infiltrating leukocytes (TILs) in a murine model of malignant melanoma. Traditional IL-2 protocols for TIL expansion support the growth of both cytotoxic and regulatory T cells, leading to inconsistent therapeutic outcomes. The research demonstrates that the novel NKG2D-retargeted IL-2 (OMCPmutIL-2) preferentially expands cytotoxic T cells, including CD8+ T cells, NK cells, and γδ T cells, enhancing their tumor-homing abilities and providing superior tumor control compared to wild-type IL-2-expanded TILs.
Creative Biolabs significantly contributed to this research by providing the H-2kb/OVA (SINFEKL) MHC Tetramer (Cat#: MHC-LC649). This product was essential for the detailed flow cytometric analysis and characterization of the TILs. The tetramer allowed for the precise identification and sorting of OVA-specific CD8+ T cells within the tumor microenvironment, facilitating the study of their expansion and function under the influence of the novel OMCPmutIL-2 cytokine. This contribution was crucial for demonstrating the superior tumor control achieved with the retargeted IL-2 therapy.

Stoner, Sara N., Joshua J. Baty, and Jessica A. Scoffield. "Pseudomonas aeruginosa polysaccharide Psl supports airway microbial community development." The ISME journal 16.7 (2022): 1730-1739.

This study explores the role of Pseudomonas aeruginosa polysaccharide Psl in the development of airway microbial communities, specifically within the context of cystic fibrosis (CF). The research focuses on interactions between P. aeruginosa and Streptococcus salivarius, demonstrating that Psl promotes biofilm formation by S. salivarius. The study employs both in vitro and in vivo models to show that S. salivarius uses a maltose-binding protein, MalE, to interact with Psl, facilitating its incorporation into the CF airway biofilm and potentially contributing to lung stability in CF patients.
Creative Biolabs provided the FITC-conjugated α-Psl antibody (Cat#: MOB-0286MC) used in the immunofluorescence and confocal laser scanning microscopy experiments. This antibody was crucial for visualizing the spatial relationship between Psl and S. salivarius within dual biofilms, allowing researchers to confirm the role of Psl in promoting S. salivarius biofilm formation and understanding the structural changes in the biofilm architecture.

Dukhovny, Anna, Amir Shlomai, and Ella H. Sklan. "The antiviral protein Viperin suppresses T7 promoter dependent RNA synthesis-possible implications for its antiviral activity." Scientific Reports 8.1 (2018): 8100.

This study explores the antiviral activity of viperin, an interferon-inducible protein, focusing on its ability to inhibit RNA synthesis mediated by bacteriophage T7 polymerase in mammalian cells. The researchers demonstrated that viperin significantly reduces cytoplasmic RNA levels by specifically inhibiting T7 polymerase-dependent RNA synthesis without affecting RNA polymerase II-dependent transcription. This inhibition is shown to be specific to viperin, as other interferon-stimulated genes did not exhibit similar effects. The study also investigated the structural domains of viperin necessary for its inhibitory activity, finding that mutations in these domains abolished its function. This research provides insights into the broad-spectrum antiviral mechanisms of viperin and its potential role in inhibiting viral RNA synthesis across different species.
Creative Biolabs provided the anti-T7 polymerase antibody (Cat# MOB-0296MC) used in the Western blot analysis. This antibody was crucial for detecting T7 polymerase protein levels in various experimental setups, allowing the researchers to confirm that viperin does not affect the stability of T7 polymerase but specifically inhibits its RNA synthesis activity. By enabling accurate detection and analysis of T7 polymerase, Creative Biolabs' antibody supported the study's investigation into the mechanisms underlying viperin's antiviral functions.

Gehrlein, Alexandra, et al. "Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct." Nature communications 14.1 (2023): 2057.

This study investigates the development of a therapeutic strategy targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase (GCase) deficiency, which is linked to Gaucher's disease and Parkinson's disease. Researchers engineered a brain-penetrant enzyme construct, GCase-BS, combining β-glucocerebrosidase with a transferrin receptor-binding moiety to facilitate its passage across the blood-brain barrier. The GCase-BS construct showed improved lysosomal uptake and function, effectively reducing pathological lipid accumulations in cellular and mouse models.
Creative Biolabs provided the HRP-conjugated pAb anti-hFab(CH1) antibody (Cat# MOB-0361MC) used in this study. This antibody was essential for measuring IgG levels of the GCase-BS molecules after incubation in mouse plasma. By enabling accurate detection and quantification of IgG levels, the antibody from Creative Biolabs supported the researchers in assessing both the enzymatic activity of GCase and the stability of the GCase-BS constructs, thereby contributing to the evaluation of their therapeutic potential.

Roubidoux, Ericka Kirkpatrick, et al. "Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2." Scientific Reports 13.1 (2023): 17820.

This study investigates the utility of nasal swabs for assessing mucosal immune responses to SARS-CoV-2. The researchers developed a novel methodology to measure cytokine and antibody responses in the nasal epithelium using nasopharyngeal swabs collected before and after SARS-CoV-2 infection or vaccination. They compared these mucosal responses to systemic responses, finding distinct cytokine profiles in nasal versus plasma samples. The study also examined the kinetics of nasal IgA and IgG antibodies post-infection and vaccination, highlighting the importance of mucosal immunity in respiratory infections.
Creative Biolabs provided the HRP-conjugated anti-human IgG antibody (Cat# MOB-0361MC) used in the total IgG ELISA assays. This antibody was crucial for detecting and quantifying IgG levels in nasal swab samples, allowing the researchers to accurately measure SARS-CoV-2 specific IgG responses. By enabling precise quantification of IgG, the antibody from Creative Biolabs supported the study's exploration of the dynamics of mucosal antibody responses, contributing to a better understanding of immunity at the nasal epithelium.

Choi, Seong Jin, et al. "KIR+ CD8+ and NKG2A+ CD8+ T cells are distinct innate-like populations in humans." Cell Reports 42.3 (2023).

This study explores the heterogeneity among human KIR+CD8+ and NKG2A+CD8+ T cells, identifying them as distinct innate-like populations with different cytokine responsiveness. The research demonstrates that KIR+CD8+ T cells exhibit IL-15-induced NK-like cytotoxicity, while NKG2A+CD8+ T cells show IL-12/IL-18-induced IFN-gamma production. It was observed that KIR+CD8+ T cells are more terminally differentiated and replicative senescent compared to NKG2A+CD8+ T cells, which are more responsive to IL-12 and IL-18 due to the high expression of these receptors induced by the transcription factor PLZF.
At Creative Biolabs, we provided essential reagents for this study, including the anti-NKG2A antibody (Cat#: TAB-437CQ) and the IgG4 isotype control (Cat# MOB-0408ZL) used in the flow cytometry analyses. Our products were crucial in identifying the distinct functional roles and cytokine responses of these T cell subsets. This research underscores the importance of understanding the diverse functions of T cell populations in developing targeted immunotherapies, highlighting our commitment to advancing immunological research and innovative therapeutic solutions.

Lamtha, Thomanai, et al. "Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development." Protein Engineering, Design and Selection 34 (2021): gzab030.

This study focuses on generating nanobodies targeting the HER2 tyrosine kinase domain, which is significant in HER2-positive breast cancer therapy. The research aimed to produce smaller, single-domain antibodies (nanobodies) to overcome limitations associated with conventional monoclonal antibodies, such as large size and resistance issues. Using phage display technology, the researchers identified three specific anti-HER2-TK nanobodies, with clone VHH17 showing the highest HER2 kinase inhibition activity. The study highlighted the potential of VHH17 as an effective therapeutic agent for treating HER2-positive breast cancer, demonstrating its ability to significantly decrease the viability of HER2-positive cancer cells.
Creative Biolabs played a crucial role in this research by providing essential reagents. Specifically, they supplied the rabbit anti-VHH antibody (Cat# MOB-099CQ) used in the ELISA binding affinity determination experiments. This reagent was vital for detecting the binding interactions between the selected nanobodies and HER2-TK, enabling the researchers to assess the specificity and efficacy of the nanobodies. The involvement of Creative Biolabs' products facilitated the detailed characterization and validation of the nanobody VHH17, which contributed significantly to the advancement of this therapeutic strategy for HER2-positive breast cancer.

Damman, Reinier, et al. "Development of in vitro-grown spheroids as a 3D tumor model system for solid-state NMR spectroscopy." Journal of Biomolecular NMR 74.8 (2020): 401-412.

This study explores the use of in vitro-grown spheroids as a three-dimensional tumor model system for solid-state NMR spectroscopy. Researchers investigated the hanging drop method to grow spheroids of uniform size and shape, suitable for studying solid tumors using solid-state NMR (ssNMR) spectroscopy. The findings revealed that these spheroids are stable under magic-angle-spinning conditions and exhibit significant metabolic differences compared to single cell preparations. Dynamic nuclear polarization (DNP)-supported ssNMR measurements demonstrated that even low concentrations of labeled nanobodies targeting EGFR (7D12) could be detected inside the spheroids. These results suggest that solid-state NMR can effectively examine proteins or other biomolecules within a 3D cellular microenvironment, offering potential applications in pharmacological research.
Creative Biolabs contributed significantly to this research by providing the rabbit-α-VHH antibody (Cat# MOB-099CQ) used for detecting 7D12. This antibody was crucial for the nanobody binding assay, which involved the detection of 7D12 binding to EGFR on A431 cells. The presence of this antibody enabled precise measurement of fluorescence intensity, helping to quantify the binding curve of 7D12. This contribution was essential for verifying the functionality and penetration of 7D12 into the spheroids, thereby facilitating detailed structural and functional studies of the proteins within the tumor model system.

Singh, Sunanda, et al. "Suppression of breast cancer cell proliferation by selective single-domain antibody for intracellular STAT3." Breast cancer: basic and clinical research 12 (2018): 1178223417750858.

This study investigated the suppression of breast cancer cell proliferation through the use of a selective single-domain antibody targeting intracellular STAT3, a transcription factor known to be constitutively activated in many human malignancies. The researchers generated a variable region of camelid heavy chain (VHH) antibody named SBT-100 (anti-STAT3 B VHH13) by immunizing camelids with human STAT3. The antibody specifically binds to STAT3 and its phosphorylated form (p-STAT3), thereby inhibiting their function. The efficacy of SBT-100 was tested in various breast cancer cell lines and a xenograft model using athymic mice, demonstrating significant inhibition of tumor growth and cell proliferation without any observable toxicity.
Creative Biolabs provided the phagemid pCDisplay-3M used in the construction of the VHH library and the VHHs against STAT3 (Cat#: MOB-113CQ) for immunoprecipitation assays. These VHHs were crucial for isolating STAT3-specific antibodies. The tools supplied by Creative Biolabs were essential in generating and characterizing the VHH antibodies that specifically target STAT3. This enabled the researchers to demonstrate the potential therapeutic effects of SBT-100 in suppressing breast cancer cell proliferation and tumor growth.

Ozer, Egon A., et al. "Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria." Nature communications 13.1 (2022): 688.

This study focused on the genomic surveillance of SARS-CoV-2 in Nigeria, particularly in Oyo state, from July 2020 to August 2021. It involved whole-genome sequencing of 378 SARS-CoV-2 isolates, revealing the dominance of the Alpha (B.1.1.7) and Eta (B.1.525) lineages during early 2021. The research highlighted that Eta lineage outcompeted Alpha and persisted even after the introduction of the Delta variant. The study used pseudotyped virus systems to demonstrate that mutations in the Spike protein of Eta isolates enhanced viral entry and reduced the neutralization capacity of antibodies from previously infected individuals. However, antibodies from vaccinated individuals remained effective. The findings emphasized the need for ongoing genomic surveillance to understand and mitigate the impact of SARS-CoV-2 variants in under-sampled regions.
In this study, Creative Biolabs provided the anti-RBD antibody CR3022 (Cat# MRO-1214LC), used to create a standard curve for ELISA assays. This antibody played a crucial role in quantifying the binding capacity of serum antibodies to the receptor-binding domain (RBD) of the virus. The accurate measurement of antibody responses was vital for assessing the immune evasion capabilities of the Eta lineage and the effectiveness of vaccine-induced immunity against this variant. The contribution of Creative Biolabs' product significantly enhanced the reliability and accuracy of the study's immunological assessments .

Gunawardana, Manjula, et al. "Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance study." Communications medicine 2.1 (2022): 129.

The study aimed to deeply understand the early dynamics of SARS-CoV-2 infection and the associated immune responses in unvaccinated individuals. Conducted from November 2020 to March 2021, it monitored nine participants intensely over three months. This longitudinal surveillance revealed rapid early viral replication with a median doubling time of 3.1 hours, followed by a slow and varied clearance phase. The study employed Bayesian modeling to describe these kinetic processes, providing valuable insights into viral transmission and infection progression, which are crucial for public health measures and clinical management of COVID-19.
Creative Biolabs significantly contributed to this study by providing crucial reagents for antibody quantification. Specifically, they supplied the control anti-SARS-CoV S antibody CR3022 (Cat#: MRO-1214LC) in IgG, IgM, and IgA formats (Cat#: N/A). This antibody was essential in the enzyme-linked immunoassay (ELISA) used to measure serum anti-receptor-binding domain (RBD) antibodies, enabling the accurate assessment of humoral immune responses in the participants. The precision and reliability of these measurements were pivotal in understanding the temporal decay profiles of different antibodies and the overall immune response dynamics in the study.

Simons, Lacy M., et al. "De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients." Transplant Infectious Disease 24.6 (2022): e13914.

This study investigates the emergence of SARS-CoV-2 spike mutations in immunosuppressed patients with persistent infections. The research focused on two patients, referred to as Patient A and Patient B, who both experienced prolonged SARS-CoV-2 infections. Nasopharyngeal and plasma specimens were collected over time to analyze viral mutations. Whole genome sequencing revealed the intrahost evolution of spike mutations, including E484K, E484Q, and deletions at positions 241-243. These mutations were linked to reduced neutralization by antibodies and impaired viral entry efficiency. The study emphasizes the role of persistent infections in the evolution of SARS-CoV-2 variants and highlights the need for ongoing antiviral drug development.
Creative Biolabs contributed significantly to this research by providing the anti-RBD antibody CR3022 (Cat# MRO-1214LC), used in enzyme-linked immunoassays (ELISA) to quantify antibody titers against the spike protein's receptor-binding domain. This antibody was crucial in determining the immune response of the patients, specifically in assessing the levels of antibodies targeting the spike protein. The use of CR3022 enabled the researchers to evaluate the impact of the emergent mutations on antibody neutralization, thus playing a key role in understanding how these mutations facilitate immune escape.

Huo, Jiandong, et al. "Neutralization of SARS-CoV-2 by destruction of the prefusion spike." Cell host & microbe 28.3 (2020): 445-454.

The study investigated the neutralization capabilities of the CR3022 monoclonal antibody against SARS-CoV-2. The researchers determined that CR3022 binds tightly to the receptor-binding domain (RBD) of the virus, demonstrating a unique mechanism of action. Unlike other antibodies that block the virus by preventing it from binding to the ACE2 receptor, CR3022 destabilizes the virus's spike protein, which leads to its neutralization. This study utilized surface plasmon resonance (SPR) and bio-layer interferometry (BLI) to measure the binding kinetics, and plaque-reduction neutralization tests (PRNT) to evaluate the antibody's efficacy. The findings suggest that CR3022 could serve as a valuable tool in the development of therapeutic strategies against COVID-19 due to its ability to neutralize the virus through a different mechanism than other known antibodies.
Creative Biolabs contributed significantly to this study by providing the CR3022 monoclonal antibody (Cat# MRO-1214LC). This antibody was crucial for the neutralization assays, enabling the researchers to demonstrate its unique neutralization mechanism. The study highlights the importance of CR3022 in understanding SARS-CoV-2's behavior and potential therapeutic interventions, underscoring the value of the high-quality reagents provided by Creative Biolabs in advancing this critical research.

Tan, Xiaotian, et al. "Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation." Biosensors and Bioelectronics 169 (2020): 112572.

This study presents a novel microfluidic ELISA technology designed for the rapid and sensitive detection of SARS-CoV-2 specific IgG antibodies in human serum. The primary objective of the research was to develop a portable diagnostic tool that can provide quantitative results within 15 minutes using only a small sample volume. The researchers identified a humanized monoclonal IgG with high binding affinity and specificity for SARS-CoV-2 S1 protein to serve as a calibration standard. By using this technology, they measured the abundance of anti-SARS-CoV-2 S1 IgG in convalescent serum from COVID-19 patients, facilitating the selection of suitable donors for convalescent plasma therapy. The study demonstrated that this technology could also detect SARS-CoV-2 antigens with high sensitivity, suggesting its potential applications in diagnostics and monitoring.
Creative Biolabs contributed significantly to this research by providing the recombinant CR3022 therapeutic antibody (Cat#: MRO-1214LC), which was used in the study for calibration and comparison purposes. The provision of this antibody was crucial for establishing the assay's accuracy and reliability in detecting SARS-CoV-2 specific antibodies. By supplying this high-quality reagent, Creative Biolabs enabled the researchers to achieve consistent and reproducible results, thereby enhancing the overall efficacy of the microfluidic ELISA platform in evaluating convalescent serum and potentially other COVID-19 related diagnostic applications.

Pillarsetty, Nagavarakishore, et al. "Oncology-inspired treatment options for COVID-19." Journal of Nuclear Medicine 61.12 (2020): 1720-1723.

This study explores the potential of the human monoclonal antibody CR3022 as a molecularly targeted radiotherapeutic agent against SARS-CoV-2, the virus responsible for COVID-19. CR3022 was labeled with iodine-131 (131I), a radioactive isotope, and its binding to the virus was assessed. The study demonstrated that 131I-CR3022 binds selectively to the SARS-CoV-2 spike protein, making it a promising candidate for both therapeutic and diagnostic purposes. The binding efficiency of the radiolabeled antibody was confirmed through a bead-based assay, indicating its potential use in Auger radiotherapy, which could inactivate the virus while minimizing damage to surrounding tissues. This approach could enhance the efficacy of COVID-19 treatments, especially when used in combination with other therapies.
Creative Biolabs significantly contributed to this research by providing the CR3022 antibody (Cat#: MRO-1214LC). The antibody, essential for the study, was successfully conjugated with iodine-131, maintaining a high purity of over 98% and specific activity of 292 MBq/mg. The high-quality antibody enabled the researchers to achieve selective and potent binding to the SARS-CoV-2 spike protein, thus facilitating the exploration of 131I-CR3022 as a targeted radiotherapeutic agent. This contribution was crucial for the study's success, highlighting Creative Biolabs' role in advancing innovative COVID-19 treatments.

Dzimianski, John V., et al. "Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry." Scientific reports 10.1 (2020): 21738.

This study focuses on developing a novel serological testing method to detect SARS-CoV-2 antibodies using biolayer interferometry (BLI-ISA). The researchers utilized the spike receptor-binding domain (RBD) antigen due to its high selectivity for SARS-CoV-2 antibodies and its correlation with virus neutralization. The BLI-ISA method was optimized to measure antigen-specific antibodies in plasma efficiently, providing a rapid, semi-quantitative evaluation. This new assay holds potential for various applications, including serosurveillance studies, evaluating antibody responses to infection and vaccination, and potentially serving as a diagnostic platform for assessing plasma antibody levels to guide convalescent plasma therapy donations.
Creative Biolabs significantly contributed to this study by supplying the Anti-SARS-CoV S Therapeutic Antibody CR3022 (Cat# MRO-1214LC). This antibody played a crucial role as a positive control in the ELISA and BLI-ISA experiments, enabling the accurate measurement and validation of antibody reactivity against the SARS-CoV-2 spike RBD. The inclusion of this reagent ensured the reliability and accuracy of the serological tests, facilitating the development of a robust and sensitive diagnostic tool.

Ahn, Terrie S., et al. "Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2." Journal of Allergy and Clinical Immunology 147.3 (2021): 876-877.

This study investigates whether commercial pre-pandemic intravenous immunoglobulin (IVIG) contains cross-reactive antibodies that can bind and neutralize SARS-CoV-2. The researchers tested 82 samples from four different brands manufactured in the United States and Europe for their ability to bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Although all samples showed cross-reactive antibodies, none demonstrated the capacity to neutralize the virus. This suggests that while IVIG can bind to SARS-CoV-2, it does not prevent viral infection. The study also explored the potential non-neutralizing effects of IVIG, such as complement fixation and antibody-dependent cellular cytotoxicity (ADCC), which might still provide therapeutic benefits.
Creative Biolabs contributed to this study by providing the anti-spike antibody CR3022 (Cat#: MRO-1214LC), which was used as a positive control in the experiments. This specific antibody was crucial in validating the binding assays, allowing the researchers to compare the binding efficacy of the commercial IVIG samples. By using CR3022, the study could accurately assess the presence of cross-reactive antibodies and their binding capabilities, thus highlighting the role of Creative Biolabs' product in ensuring the reliability and accuracy of the experimental results.

Demonbreun, Alexis R., et al. "Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure." JCI insight 6.9 (2021).

This study investigated the prevalence and durability of IgG antibodies against SARS-CoV-2 in a diverse urban population. Conducted between June and December 2020, the research recruited 7935 participants through electronic advertising and minimal-contact methods. Participants provided self-sampled dried-blood spots (DBS) for laboratory analysis of IgG antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The findings revealed an overall seroprevalence of 17.9%, indicating a significant underestimation of COVID-19 exposure when relying solely on viral testing. The study demonstrated that asymptomatic and mildly symptomatic individuals produced IgG levels comparable to those documented in non-hospitalized COVID-19 cases, suggesting a widespread exposure across the community.
Creative Biolabs played a crucial role in this study by supplying the CR3022 antibody (Cat# MRO-1214LC), which was essential for the quantitative measurement of anti-RBD IgG levels. This antibody was used to calibrate the ELISA protocol, allowing the researchers to accurately quantify the concentration of IgG in the participants' samples. The high specificity and sensitivity of the CR3022 antibody enabled the reliable detection and measurement of SARS-CoV-2 exposure in the studied population, significantly contributing to the understanding of antibody persistence and the immune response to the virus.

Rauch, Susanne, et al. "mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents." npj Vaccines 6.1 (2021): 57.

The study investigates the efficacy and safety of the mRNA-based SARS-CoV-2 vaccine candidate, CVnCoV, developed by CureVac. The CVnCoV vaccine encodes the full-length, pre-fusion stabilized spike protein of SARS-CoV-2 and is encapsulated in lipid nanoparticles. The study demonstrates that CVnCoV induces robust humoral and cellular immune responses, leading to high titers of virus-neutralizing antibodies and balanced T-cell responses in rodent models. Vaccinated hamsters showed significant protection from SARS-CoV-2 challenge, evidenced by the absence of viral replication in the lungs and no signs of vaccine-enhanced disease, even at suboptimal doses. These findings support the potential of CVnCoV as a potent and safe vaccine candidate against COVID-19.
Creative Biolabs played a crucial role in this research by supplying the Human anti-SARS-CoV S antibody (Cat# MRO-1214LC) used for specific S protein expression assessment. This product was instrumental in verifying the protein's correct expression and modification, essential for the vaccine's efficacy testing. The accurate and reliable detection of the SARS-CoV-2 spike protein facilitated the comprehensive evaluation of the immune responses induced by CVnCoV, contributing significantly to the study's overall success.

Dawson, Erica D., et al. "Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses." Journal of Virological Methods 291 (2021): 114111.

This study focused on the development and validation of a multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses, specifically the VaxArray Coronavirus (CoV) SeroAssay. The assay aims to enhance clinical trials by providing rapid, sensitive, and precise quantification of IgG antibodies against nine coronavirus spike antigens. The study demonstrated the assay's capability to measure antibody responses with high precision and accuracy, achieving a lower limit of quantification ranging from 0.3 to 2.0 ng/mL and a linear dynamic range of 76 to 911-fold. Clinical performance was evaluated using 263 human serum samples, yielding a positive percent agreement (PPA) of 98.5% and a negative percent agreement (NPA) of 100%. This assay is particularly useful for monitoring antibody responses in COVID-19 vaccine candidates, streamlining the process of understanding immune responses post-vaccination.
Creative Biolabs provided the CR3022 monoclonal antibody targeting the spike proteins of SARS-CoV-1 (Cat#: MRO-1214LC), which was used in the study to evaluate the specificity and linear dynamic range of the VaxArray CoV SeroAssay. The CR3022 antibody specifically binds to the nCoV(ii) receptor binding domain (RBD) antigen and the SARS antigen. The inclusion of this antibody was crucial in demonstrating the assay's ability to accurately measure antibody responses to multiple coronavirus antigens. The use of Creative Biolabs' antibody enabled the researchers to validate the performance of the assay, ensuring its reliability and precision in detecting and quantifying antibodies, thereby contributing significantly to the study's success.

Ibarrondo, F. Javier, et al. "Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19." New England Journal of Medicine 383.11 (2020): 1085-1087.

The study focused on the rapid decay of anti-SARS-CoV-2 antibodies in individuals who recovered from mild COVID-19. Conducted with 34 participants, most of whom had mild symptoms, the research aimed to measure and quantify the levels of IgG antibodies targeting the spike receptor-binding domain over a period of up to 119 days post-symptom onset. The study found that antibody levels decreased significantly over time, raising concerns about the longevity of humoral immunity in those with mild COVID-19 and suggesting potential implications for immunity passports, herd immunity, and vaccine durability.
Creative Biolabs played a crucial role in this research by providing the control monoclonal IgG CR3022 (Cat#: MRO-1214LC) used in the enzyme-linked immunosorbent assay (ELISA) to detect and quantify the anti-SARS-CoV-2 spike receptor-binding domain IgG levels. The use of CR3022 was essential in the precise quantification of antibody levels, which enabled the study to accurately track the rate of antibody decay in the participants.

Tan, Xiaotian, et al. "Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples." BioRxiv (2020): 2020-04.

This study presents the development of a microfluidic ELISA technology designed for the rapid, quantitative, and sensitive detection of SARS-CoV-2 biomarkers. By using SARS-CoV-2 specific IgG and viral antigens spiked in serum as a model system, the researchers aimed to provide a point-of-care diagnostic tool that overcomes the limitations of current popular detection methods, such as lateral-flow test strips and conventional ELISA. The microfluidic ELISA device requires minimal sample volumes, is highly portable, and delivers results within 15-20 minutes. This innovative approach not only facilitates the rapid analysis of COVID-19 patients and vaccine recipients but also allows for the swift affinity evaluation of monoclonal anti-S1 antibodies.
Creative Biolabs played a crucial role in this study by providing essential reagents and antibodies that were pivotal to the research. Specifically, the study utilized the human-cell-expressed SARS-CoV Spike S1-His recombinant protein (Cat#: VAng-Wyb7337) and the recombinant CR3022 therapeutic antibody (Cat#: MRO-1214LC), both supplied by Creative Biolabs. These products were instrumental in the detection and characterization of SARS-CoV-2 specific IgG, contributing significantly to the development and validation of the microfluidic ELISA platform. The availability and quality of these reagents ensured the accuracy and reliability of the results, ultimately aiding in the advancement of rapid diagnostic technologies for COVID-19.

Tada, Takuya, et al. "Prophylaxis and treatment of SARS-CoV-2 infection by an ACE2 receptor decoy in a preclinical animal model." Iscience 26.2 (2023).

The study conducted by Takuya Tada and colleagues focuses on the development and testing of a high-affinity ACE2 receptor decoy to combat SARS-CoV-2 infection, including variants like Omicron. The decoy, a modified ACE2 ectodomain fused to an immunoglobulin heavy chain Fc region, was shown to significantly suppress virus loads in preclinical animal models. The decoy demonstrated potent neutralizing activity against various SARS-CoV-2 variants, both in vitro and in vivo, by preventing the virus from binding to the ACE2 receptor on host cells. This approach offers a promising prophylactic and therapeutic strategy against current and potentially future SARS-CoV-2 variants, given its ability to target the conserved ACE2 binding mechanism of the virus.
Creative Biolabs played a crucial role in this study by providing the anti-p24 monoclonal antibody AG3.0 (Cat#: MRO-961CQ). This antibody was essential for the virion-decoy pull-down assay, which involved binding decoy proteins to nickel-nitrilotriacetic acid-agarose beads, incubating with spike protein-pseudotyped virus, and analyzing bound virions on an immunoblot. The anti-p24 antibody AG3.0 enabled the detection of bound virions, facilitating the evaluation of the decoy protein's efficacy in neutralizing the virus. This contribution was significant as it provided a key reagent necessary for the successful execution and analysis of the assay.

Chatterjee, Shilpak, et al. "CD38-NAD+ axis regulates immunotherapeutic anti-tumor T cell response." Cell metabolism 27.1 (2018): 85-100.

This study investigates the role of CD38-mediated NAD+ metabolism in the anti-tumor function of T cells. The researchers explored how CD38 expression influences the metabolic pathways of T cells within the tumor microenvironment, specifically focusing on its impact on mitochondrial biogenesis and function. By analyzing CD38-deficient and wild-type T cells, the study demonstrated that CD38 plays a crucial role in regulating NAD+ levels, which in turn affects the T cells' metabolic fitness and anti-tumor capabilities. The findings suggest that targeting CD38 could enhance the efficacy of T cell-based immunotherapies by improving T cell metabolism and function within tumors.
Creative Biolabs provided critical reagents for this study, including the Anti CD38 VHH Single Domain Antibody (Cat# NABL-079). This antibody was essential for the experiments involving CD38 detection and functional analysis in T cells. By enabling precise measurement and modulation of CD38 activity, the antibody facilitated a deeper understanding of how CD38 regulates T cell metabolism and its potential as a therapeutic target. The contribution of Creative Biolabs' products significantly advanced the study's investigation into enhancing T cell-mediated anti-tumor responses through metabolic modulation.

Zhu, Ke, et al. "The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease." Science Translational Medicine 15.714 (2023): eabq6492.

This study investigates the role of the D2D3 form of the soluble urokinase plasminogen activator receptor (suPAR) in the development of diabetes and kidney disease. The research found that D2D3 acts as an immunotoxin, leading to kidney disease and insulin-dependent diabetes mellitus in transgenic mice fed a high-fat diet. These mice exhibited symptoms such as microalbuminuria, elevated serum creatinine, glomerular hypertrophy, decreased insulin and C-peptide levels, impaired glucose-stimulated insulin secretion, and reduced pancreatic β cell mass. The study demonstrated that targeting D2D3 could potentially serve as a therapeutic approach for treating kidney diseases and insulin-dependent diabetes mellitus.
Creative Biolabs played a crucial role in this study by providing the anti-uPAR monoclonal antibodies used for immunoprecipitation and Western blot analyses. Specifically, the anti-uPAR antibody ATN615 (Cat#: PABC-130) from Creative Biolabs was utilized to detect the presence of D2D3 in human sera and mouse samples. These products were instrumental in identifying the pathogenic role of D2D3 and validating the effectiveness of anti-uPAR antibody treatment in restoring β cell mass and function in D2D3 transgenic mice. The contributions of Creative Biolabs' reagents were vital in enabling the detailed examination of D2D3's impact on kidney and pancreatic functions.

Schiffmann, Lars Mortimer, et al. "Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer." British journal of cancer 120.1 (2019): 69-78.

This study investigates the impact of tumour-infiltrating neutrophils on the efficacy of anti-VEGF therapy in metastatic colorectal cancer. It highlights that the presence of CD177+ neutrophils in tumors is an adverse prognostic factor for patients treated with bevacizumab, an antibody targeting vascular endothelial growth factor (VEGF). The study demonstrates that a novel bi-specific anti-VEGF/anti-Ang2 compound, BI-880, can overcome resistance to VEGF inhibition by reducing hypoxia and improving vascular normalization in experimental models.
At Creative Biolabs, we are proud to have contributed to this important research by providing the anti-VEGF antibody B20 used in the syngeneic tumor models. Our role was crucial in evaluating the efficacy of BI-880 in combination with VEGF inhibition. This study underscores the potential of combined VEGF/Ang2 inhibition as a promising strategy to enhance treatment outcomes for colorectal cancer patients, highlighting our commitment to advancing cancer research and innovative therapeutic solutions.

Marcink, Tara C., et al. "Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms." Science Advances 9.6 (2023): eade2727.

The study aims to investigate the structure of the fusion complex of human parainfluenza virus 3 (HPIV3) using cryo-electron tomography. It specifically focuses on the interaction between the hemagglutinin-neuraminidase (HN) and fusion (F) proteins, which are essential for viral entry into host cells. By visualizing these proteins at subnanometer resolution, the researchers were able to detail how HN and F proteins remain in a quiescent state on the viral surface until activation and how HN facilitates F's role in the fusion process. This research provides insights into the mechanisms of viral entry and potential targets for antiviral therapies.
Creative Biolabs contributed to this research by supplying the PIA174 antibody Fab fragment (Cat# PABJ-0161-F(E)) and full antibody (Cat# PABJ-0161) used in the study. The catalog number for these products is not explicitly mentioned in the document. These antibodies were crucial for structural studies, allowing the researchers to stabilize and visualize the prefusion F complex and understand the precise interaction between HN and F proteins. The use of these antibodies facilitated the detailed examination of the viral fusion mechanism, which is essential for developing strategies to prevent viral entry into host cells.

Maniv, Inbal, et al. "Altered ubiquitin signaling induces Alzheimer's disease-like hallmarks in a three-dimensional human neural cell culture model." Nature Communications 14.1 (2023): 5922.

The study investigates the role of altered ubiquitin signaling in inducing Alzheimer's disease (AD)-like hallmarks using a three-dimensional human neural cell culture model. It highlights that the accumulation of the UBB+1 protein is an early event in Alzheimer's disease. The research demonstrates that UBB+1 expression induces AD pathology in human neurons by interacting with UCHL1 and altering APP protein levels. Notably, silencing UBB+1 expression rescues AD pathology in human familial AD (FAD) neurons.
Creative Biolabs significantly contributed to this study by providing the 3D6 anti-amyloid-β antibody (Cat. no. PABL-011), which was used in immunofluorescence staining experiments. The use of this antibody was crucial for detecting amyloid-β aggregates, a key pathological feature of Alzheimer's disease, thus enabling the researchers to better understand and visualize the AD-like pathology in their 3D neural cell culture model.

Tan, Thomas CJ, et al. "Translation factor eIF5a is essential for IFNγ production and cell cycle regulation in primary CD8+ T lymphocytes." Nature Communications 13.1 (2022): 7796.

This study investigates the essential role of the translation factor eIF5a in the production of interferon-gamma (IFNγ) and the regulation of the cell cycle in primary CD8+ T lymphocytes. The research demonstrates that eIF5a is dynamically regulated through post-translational modification in naïve CD8+ T cells upon activation, facilitating the translation of specific subsets of proteins crucial for long-term survival and effector functions. The study underscores the importance of eIF5a in the coordination of immune responses by controlling the translation of mRNAs that regulate proliferation and key effector functions, including the production of IFNγ.
At Creative Biolabs, we supplied the hypusine antibody Hpu24 (Cat#: PABL-202) used in flow cytometry and Western blotting analyses. Our products were crucial in enabling the detailed examination of eIF5a's role in T cell activation and function. This study's significance lies in its potential to uncover new therapeutic targets for enhancing immune responses and treating conditions related to immune dysfunction, highlighting our commitment to advancing immunological research and innovative solutions.

Park, Jae-Keun, et al. "Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model." Nature medicine 26.8 (2020): 1240-1246.

This study investigates the selection of an HA stalk antibody-escape mutant virus in human influenza challenge participants. The researchers focused on a well-characterized influenza A virus stock containing a mixed population of wild-type and mutant viruses with a nonsynonymous single-nucleotide polymorphism (SNP) in the HA stalk (A388V). They analyzed pre-existing anti-HA stalk antibody levels and post-challenge viral shedding in participants, revealing that higher pre-challenge anti-HA stalk antibody titers were associated with the selection of the mutant virus. The study found that the A388V mutation conferred resistance to some broadly neutralizing monoclonal antibodies (bNAbs) and was rapidly selected under immune pressure, highlighting a potential challenge for HA-stalk-targeting universal influenza vaccines.
Creative Biolabs provided several key reagents for this research, including the broadly neutralizing monoclonal antibodies CR9114 (Cat#: PABX-119), FI6V3 (Cat#: PABL-214), and CT149 (Cat#: PABL-213). These antibodies were essential for evaluating the binding and neutralization characteristics of the mutant and wild-type viruses. The specific contributions of these antibodies were crucial for understanding the structural changes and resistance mechanisms conferred by the A388V mutation, thereby aiding in the comprehensive analysis of HA stalk antibody escape and its implications for vaccine development.

Tang, Wei, et al. "Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in respiratory syncytial virus fusion protein." Journal of Virology 95.20 (2021): 10-1128.

This study investigates the mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in the respiratory syncytial virus (RSV) fusion protein. The researchers employed a dual-luciferase protocol to discover LF-6, a small-molecule inhibitor that targets the RSV fusion glycoprotein. They found that the K394R mutation not only conferred resistance to LF-6 but also to other RSV fusion inhibitors, including those in clinical development. This mutation destabilizes the F protein and enhances its membrane fusion activity, increasing viral resistance. The study highlights the need for alternative strategies to combat RSV infections, given the resistance risks posed by the K394R mutation.
In this research, Creative Biolabs provided crucial reagents that facilitated the experiments. Specifically, the D25 monoclonal antibody (Cat# PABL-322) and Motavizumab (Cat# TAB-709) were used for detecting RSV F protein in various assays, including the immunofluorescence and cell-surface triggering assays. These antibodies were essential for accurately identifying the effects of mutations on the RSV F protein and assessing the resistance mechanisms. The products from Creative Biolabs significantly contributed to the detailed analysis and validation of the findings related to the K394R mutation and its impact on RSV fusion inhibitor resistance.

Gilbert, Brian E., et al. "Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge." Vaccine 36.52 (2018): 8069-8078.

This study focused on the development and evaluation of an RSV F nanoparticle vaccine targeting human respiratory syncytial virus (RSV), which is a major cause of severe respiratory infections in various vulnerable populations, including newborns and the elderly. The RSV F nanoparticle vaccine was designed to induce a broad polyclonal antibody response against multiple neutralizing epitopes on the fusion (F) protein of RSV. These antibodies were shown to neutralize both wild-type RSV and palivizumab-resistant mutant strains in animal models, particularly in cotton rats. The vaccine's efficacy was enhanced with the use of an aluminum phosphate adjuvant, which significantly increased the antibody avidity and protection against RSV challenges.
Creative Biolabs contributed to this study by providing the monoclonal antibody D25 (Cat#: PABL-322), which was used for competitive binding assays to characterize the antibody responses elicited by the RSV F nanoparticle vaccine. The D25 antibody specifically targets antigenic site Ø on the pre-fusion F conformation of the RSV F protein. The inclusion of this antibody was crucial for demonstrating that the vaccine-induced antibodies could bind to conserved epitopes on both pre-fusion and post-fusion F conformations, supporting the vaccine's potential to provide broad protection against RSV.

Girard, Pauline, et al. "Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes." Clinical & Translational Immunology 10.11 (2021): e1329.

This study investigates the dysfunctional BTN3A and its interaction with deregulated immune checkpoints and type I/II interferons in the context of melanoma. The research focuses on the roles of plasmacytoid dendritic cells (pDCs) and gamma-delta (γδ) T cells, examining their phenotypic and functional interactions in both the blood and tumor microenvironment of melanoma patients. The study highlights severe alterations in the bidirectional cross-talk between pDCs and γδ T cells in melanoma, noting that while healthy pDCs can drive potent activation of γδ T cells, those from melanoma patients exhibit impaired functionality.
Creative Biolabs provided critical reagents for this study, specifically anti-BTN3A agonist antibody (clone 20.1, Cat# PABL-414) and anti-BTN3A blocking antibody (clone 103.2, Cat# PABL-415). These antibodies were used to assess the functionality of BTN3A on γδ T cells and pDCs within PBMCs and tumor infiltrates. The use of these antibodies was essential in revealing the potential functional impairment of BTN3A in melanoma patients, thereby providing insights into the therapeutic targeting of BTN3A to improve immune responses in cancer therapy.

Girard, Pauline, et al. "Potent bidirectional cross-talk between plasmacytoid dendritic cells and γδT cells through BTN3A, type I/II IFNs and immune checkpoints." Frontiers in Immunology 11 (2020): 861.

This study investigates the potent bidirectional cross-talk between plasmacytoid dendritic cells (pDCs) and γδ T cells through BTN3A, type I/II interferons, and immune checkpoints. By co-culturing purified human pDCs and γδ T cells in the presence of various stimulants such as TLR-L, PAg, and zoledronate (Zol), the researchers aimed to mimic both infectious and tumor settings. The study found that TLR7/9L- or Zol-stimulated pDCs drive robust γδ T cell activation, Th1 cytokine secretion, and cytotoxic activity. Conversely, PAg-activated γδ T cells induce phenotypic changes and functional activities in pDCs. The study highlights the crucial interplay between these immune players, suggesting that exploiting this interaction could offer novel immunotherapeutic strategies for cancers, infections, and autoimmune diseases.
Creative Biolabs contributed to this research by providing the anti-BTN3A blocking antibody (Cat# PABL-415). This antibody was pivotal in experiments aimed at blocking BTN3A, a molecule critical in the pDC-γδ T cell cross-talk. The use of this antibody allowed the researchers to delineate the role of BTN3A in the activation and modulation of immune responses between pDCs and γδ T cells, thereby supporting the study's exploration of new therapeutic approaches targeting these interactions.

Farrington, Lila A., et al. "Opsonized antigen activates Vδ2+ T cells via CD16/FCγRIIIa in individuals with chronic malaria exposure." PLoS Pathogens 16.10 (2020): e1008997.

This study investigates the activation and function of Vδ2+ T cells in individuals with chronic malaria exposure. It focuses on how opsonized antigens activate these T cells via the CD16/FCγRIIIa receptor. The researchers demonstrated that in individuals with repeated malaria exposure, Vδ2 T cells show reduced TCR responsiveness but increased expression of CD16. This shift allows Vδ2 T cells to respond to opsonized P. falciparum-infected red blood cells through CD16, independent of TCR engagement. The study highlights a novel activation pathway for Vδ2 T cells that might enhance the immune response against malaria in chronically exposed individuals.
Creative Biolabs provided critical reagents for this research, specifically the Butyrophilin 3A1 (BTN3A1) blocking antibody (Cat# PABL-415). This antibody was essential for experiments demonstrating that Vδ2 T cell activation via CD16 is independent of TCR engagement. By using this antibody, the researchers were able to confirm that BTN3A1 blockade did not inhibit the activation of Vδ2 T cells by opsonized antigens, thereby underscoring the significance of CD16-mediated activation pathways. The contribution of Creative Biolabs' products was crucial in elucidating these alternative activation mechanisms of Vδ2 T cells.

de Weerdt, Iris, et al. "A bispecific single-domain antibody boosts autologous Vγ9Vδ2-T cell responses toward CD1d in chronic lymphocytic leukemia." Clinical Cancer Research 27.6 (2021): 1744-1755.

This study focuses on enhancing the efficacy and reducing the toxicity of autologous T cell-based therapies for chronic lymphocytic leukemia (CLL) by utilizing a bispecific single-domain antibody that targets CD1d to activate Vγ9Vδ2-T cells. The researchers evaluated CD1d expression in 78 untreated CLL patients and generated a CD1d-specific Vγ9Vδ2-T cell engager using single-domain antibodies (VHH). They demonstrated that CD1d is expressed in the majority of CLL patients, particularly those with advanced disease, and that the bispecific engager effectively activates Vγ9Vδ2-T cells, inducing robust cytotoxic responses against CLL cells. The study highlights the potential of this approach to improve the therapeutic outcomes for CLL patients by leveraging the intrinsic immunotherapeutic properties of Vγ9Vδ2-T cells.
Creative Biolabs contributed to this research by providing the anti-BTN3A1 monoclonal antibody (Cat# PABL-415). This antibody was crucial for the experiments that involved blocking BTN3A1 to investigate the remaining phosphoantigen recognition by Vγ9Vδ2-T cells in the presence of the bispecific engager. The use of this antibody allowed the researchers to confirm the additional activation pathway of Vγ9Vδ2-T cells, thus supporting the study's goal of developing more effective and targeted immunotherapies for CLL.

Girard, Pauline, et al. "Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes." Clinical & Translational Immunology 10.11 (2021): e1329.

This study investigates the dysfunctional BTN3A and its interaction with deregulated immune checkpoints and type I/II interferons in the context of melanoma. The research focuses on the roles of plasmacytoid dendritic cells (pDCs) and gamma-delta (γδ) T cells, examining their phenotypic and functional interactions in both the blood and tumor microenvironment of melanoma patients. The study highlights severe alterations in the bidirectional cross-talk between pDCs and γδ T cells in melanoma, noting that while healthy pDCs can drive potent activation of γδ T cells, those from melanoma patients exhibit impaired functionality.
Creative Biolabs provided critical reagents for this study, specifically anti-BTN3A agonist antibody (clone 20.1, Cat# PABL-414) and anti-BTN3A blocking antibody (clone 103.2, Cat# PABL-415). These antibodies were used to assess the functionality of BTN3A on γδ T cells and pDCs within PBMCs and tumor infiltrates. The use of these antibodies was essential in revealing the potential functional impairment of BTN3A in melanoma patients, thereby providing insights into the therapeutic targeting of BTN3A to improve immune responses in cancer therapy.

Price, Joshua MJ, et al. "Detection of tissue factor-positive extracellular vesicles using the ExoView R100 system." Research and Practice in Thrombosis and Haemostasis 7.4 (2023): 100177.

This study investigates the potential of using the ExoView R100 system for the detection of tissue factor (TF)-positive extracellular vesicles (EVs) in plasma, particularly from patients with trauma and ovarian cancer. The researchers utilized an antibody-based capture system on ExoView chips to identify and quantify TF+ EVs. The study demonstrated that TF+ EVs can be effectively captured and fluorescently labeled, allowing for their measurement in both cell culture supernatant and plasma samples. The correlation between TF activity and the ExoView measurements suggests that this method could be valuable for clinical applications in identifying individuals at risk of thrombosis.
Creative Biolabs provided the anti-TF monoclonal antibody 5G9 (Cat# PABW-121), which was used as the capture antibody on the ExoView chips. This antibody was critical for the successful capture and detection of TF+ EVs, enabling the researchers to validate the ExoView system's ability to measure TF+ EVs in various biological samples accurately. The reliable performance of the 5G9 antibody from Creative Biolabs ensured the specificity and sensitivity of the assay, contributing significantly to the study's findings.

Rotondo Dottore, Giovanna, et al. "Insights into the role of DNA methylation and gene expression in graves orbitopathy." The Journal of Clinical Endocrinology & Metabolism 108.5 (2023): e160-e168.

This study investigates the role of DNA methylation and gene expression in Graves orbitopathy (GO). Researchers examined orbital fibroblasts from both GO patients and control subjects, focusing on DNA methylation under basal conditions and after exposure to an anti-thyrotropin (TSH) receptor antibody (M22) and various cytokines. The results showed a significant increase in global DNA methylation in both control and GO fibroblasts when incubated with M22. Additionally, the study identified numerous differentially methylated DNA regions and correlated these changes with altered gene expression and increased cell proliferation. The findings suggest that differential DNA methylation and gene expression in orbital fibroblasts contribute to the pathological features of GO.
Creative Biolabs provided the human monoclonal anti-TSHR antibody M22 (Cat#: PABW-172) for this study. The M22 antibody was crucial in demonstrating the link between TSHR activation and increased DNA methylation, gene expression changes, and cell proliferation in orbital fibroblasts. This contribution was essential for elucidating the epigenetic mechanisms underlying the persistent functional alterations observed in GO, thereby advancing the understanding of the disease's pathogenesis.

Ketteler, Carolin, et al. "Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen-Bethesda assay." Research and Practice in Thrombosis and Haemostasis 6.8 (2022): e12799.

This study evaluates the impact of different kinetic profiles of four FVIII monoclonal antibodies on the inhibitor titer quantification using the modified Nijmegen-Bethesda assay. The research was conducted to understand how variations in antibody kinetics can influence the accuracy of FVIII inhibitor titers, which are crucial for managing hemophilia A. The study found that different FVIII monoclonal antibodies exhibit distinct kinetic profiles, affecting the calculation of inhibitor titers. The results suggest that a more accurate titer calculation method, such as using sigmoidal regression, should be employed to account for these kinetic differences.
Creative Biolabs contributed significantly to this research by providing the human anti-FVIII monoclonal antibody BO2C11 (Cat# PABX-058). This antibody was essential for analyzing its specific kinetic profile and its effect on FVIII inhibitor titer quantification. The data derived from the use of BO2C11 helped to highlight the need for improved titer calculation methods, thus supporting the study's goal of enhancing the accuracy of FVIII inhibitor quantification in clinical settings.

Deng, Kai, et al. "Hepatitis C virus hypervariable region 1 antibodies interrupt E2-SR-B1 interaction to suppress viral infection." Iscience 26.4 (2023).

This study investigates the role of antibodies targeting the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) envelope protein in blocking viral infection. The researchers demonstrated that antibodies specific to the HVR1 region could inhibit the interaction between the HCV E2 protein and the SR-B1 receptor, which is crucial for viral entry into host cells. Through experiments with antibodies derived from chronic hepatitis C (CHC) patients and rabbits immunized with HVR1 peptides, the study showed that these antibodies could effectively neutralize multiple HCV genotypes, thereby highlighting the potential of HVR1-targeting antibodies in controlling HCV infections.
Creative Biolabs provided the monoclonal antibody AP33 (Cat# PABX-079) used to block cell-free transmission of HCV in the cell-cell transmission assays. The AP33 antibody was crucial in demonstrating the efficacy of patient-derived IgGs and HVR1-specific antibodies in inhibiting both cell-free and cell-cell transmission of the virus. This contribution was essential for validating the study's findings on the role of HVR1-targeting antibodies in preventing HCV infection and transmission.

Genovesi, Laura A., et al. "Patient-derived orthotopic xenograft models of medulloblastoma lack a functional blood-brain barrier." Neuro-oncology 23.5 (2021): 732-742.

This study evaluates the integrity and permeability of the blood-brain-tumor barrier (BBTB) in various preclinical models of medulloblastoma (MB), the most common malignant pediatric brain tumor. The researchers utilized high-resolution magnetic resonance imaging (MRI) and pharmacokinetic modeling to compare the BBTB in genetically engineered mouse models (GEMMs) and patient-derived orthotopic xenograft (PDOX) models. They discovered significant differences in BBTB integrity between models, with GEMM models showing intact BBTB, while PDOX models displayed disrupted BBTB. The study highlights the importance of considering BBTB integrity in preclinical assessments to improve the translation of novel therapeutics into clinical settings.
Creative Biolabs provided essential reagents for this research, specifically the anti-carbonic anhydrase IX (CAIX) antibody (Cat# PABZ-017). This antibody was crucial for immunohistochemistry analysis, enabling the researchers to identify and quantify hypoxic regions within tumor tissues. By providing this high-quality reagent, Creative Biolabs facilitated the study's exploration of the relationship between hypoxia and BBTB integrity, thereby supporting the overall objective of enhancing therapeutic strategies for medulloblastoma.

Limongi, Tania, et al. "Extracellular vesicles tropism: A comparative study between passive innate tropism and the active engineered targeting capability of lymphocyte-derived evs." Membranes 11.11 (2021): 886.

This study investigates the targeting capabilities of extracellular vesicles (EVs) derived from B lymphocytes. The researchers conducted a thorough immuno-phenotypic characterization of B-cell EV membranes and explored the tropism of these vesicles towards different cell lines. The study demonstrated that native EVs have an innate capability for passive targeting, which could be significantly enhanced by engineering the vesicles with anti-CD20 monoclonal antibodies. The engineered EVs showed increased internalization into target cancer cells, specifically Daudi cells, which highly express the CD20 marker, compared to HL60 cells that lack this marker.
Creative Biolabs contributed significantly to this research by providing the anti-CD20 monoclonal antibody Rituximab (Cat#: TAB-016). This antibody was crucial for engineering the EVs to enhance their targeting capability towards CD20-expressing cancer cells. The use of this antibody allowed the researchers to demonstrate the increased efficacy of the engineered EVs in selectively targeting and internalizing into the Daudi cell line, thereby validating the potential of antibody-engineered EVs for targeted cancer therapy.

Calzetta, Luigino, et al. "Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab." British Journal of Pharmacology 177.20 (2020): 4750-4765.

This study investigates the effectiveness of targeting the IL-5 pathway in addressing airway hyperresponsiveness (AHR) in asthma by comparing two monoclonal antibodies, benralizumab and mepolizumab. The research focuses on their ability to modulate AHR in human airways passively sensitized to mimic asthmatic conditions. The study measures the inhibition of AHR to histamine, parasympathetic activation, and mechanical stress, as well as the modulation of cyclic AMP (cAMP) levels. The results demonstrate that both benralizumab and mepolizumab significantly reduce AHR, with benralizumab being more potent. The study concludes that targeting the IL-5/IL-5Rα axis is an effective strategy for preventing AHR.
Creative Biolabs provided the benralizumab (Cat# TAB-222) and mepolizumab (Cat# TAB-031) used in this study. These antibodies were essential for the comparative analysis of their effects on AHR and cAMP levels in human bronchial tissues. The use of these reagents allowed the researchers to determine the differential potency and efficacy of benralizumab and mepolizumab in modulating AHR, thus contributing significantly to the understanding of their therapeutic potential in treating asthma.

Ye, Chunting, et al. "A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic-related cytokine release syndrome." The FASEB Journal 34.9 (2020): 12963.

This study focuses on developing a rapid, sensitive, and reproducible in vivo PBMC humanized murine model to determine therapeutic-related cytokine release syndrome (CRS). The researchers used NOD-scid IL2rgnull (NSG) mice engrafted with human peripheral blood mononuclear cells (PBMCs) to study CRS in response to various immunotherapeutics. The study evaluated the cytokine release profiles following treatment with monoclonal antibodies, including anti-CD3, anti-CD28, and a TGN1412 analog. The results demonstrated that these humanized mouse models effectively capture the variation in cytokine release among different donors and provide a robust platform for preclinical screening of novel therapeutics for CRS.
Creative Biolabs provided the TGN1412 analog (Cat# TAB-064LC) used in this study. This antibody was critical for evaluating the cytokine release and immune response in the humanized mouse models. By enabling the precise measurement of cytokine levels and assessing the potential of therapeutic-induced CRS, the TGN1412 analog from Creative Biolabs significantly supported the study's goal of developing a reliable preclinical model for screening immunotherapeutics.

Helwig, Michael, et al. "Neuronal hyperactivity-induced oxidant stress promotes in vivo α-synuclein brain spreading." Science advances 8.35 (2022): eabn0356.

This study investigated the effects of neuronal hyperactivity on the spreading of the Parkinson's disease-associated protein α-synuclein (αS) in the brain. Using a mouse model, researchers found that increased neuronal activity exacerbated oxidative and nitrative stress, leading to enhanced accumulation and aggregation of nitrated αS. The experiments demonstrated that hyperactivity significantly promoted the interneuronal transfer and brain-wide distribution of αS, suggesting a mechanistic role of oxidant stress in facilitating the protein's spread. The study employed advanced genetic and viral techniques to modulate neuronal activity and track the movement of αS across different brain regions, providing valuable insights into the pathophysiological processes underlying neurodegenerative diseases.
Creative Biolabs played a crucial role in this research by supplying key reagents. They provided the Syn-O2 antibody (Cat#: TAB-0748CLV) used for double fluorescence labeling. This involved incubating sections with anti-RFP or mouse anti-Syn-O2, followed by anti-h-αS, and labeling with secondary antibodies conjugated with DyLight 488 or DyLight 594. These reagents were essential for the immunofluorescence analysis, enabling precise detection and visualization of protein interactions and modifications within the study.

Simon, Isak. "Expression & affinity analysis of recombinant RX against pathogenic α-synuclein." (2021).

This study investigated the potential of recombinant RX protein constructs as a therapeutic approach to counteract the pathogenesis of Parkinson's disease by targeting the neurotoxic oligomers of α-synuclein. The research aimed to express, purify, and trimerize two RX protein constructs (D1 and D123mut) to study their binding affinity to α-synuclein monomers and oligomers using various methods, including ELISAs. The findings indicated that while D123 showed some binding affinity to α-synuclein oligomers in indirect ELISA, D1 and D123mut did not exhibit sufficient purity or binding capability. The study concluded that optimization of protein constructs and methods is crucial for further exploring RX as a therapeutic protein against Parkinson's disease.
Creative Biolabs provided key reagents and products crucial for this study. Specifically, the Anti-Human SNCA Therapeutic Antibody (Syn-O2, CAT#: TAB-0748CLV) was used as a positive control in the ELISA assays to validate the binding affinity of RX constructs to α-synuclein. Additionally, Creative Biolabs' product ensured reliable comparisons and facilitated the validation process, thereby playing a significant role in the experimental procedures and overall findings of the study.

Sela, Mor, et al. "Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease." Advanced Materials 35.51 (2023): 2304654.

This study explores the development and effectiveness of brain-targeted liposomes (BTL) loaded with monoclonal antibodies (mAbs) to reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson's disease (PD). The researchers engineered liposomes conjugated with transferrin to enhance their delivery across the blood-brain barrier (BBB). These liposomes were loaded with the SynO4 antibody, which inhibits alpha-synuclein aggregation, a key pathological feature of PD. The study demonstrated that BTL effectively crossed the BBB, were taken up by neurons, and significantly reduced alpha-synuclein aggregation and neuroinflammation in mouse models of PD. Additionally, BTL treatment improved motor function and learning abilities in these models, showcasing the potential of this targeted delivery system for treating neurodegenerative diseases.
Creative Biolabs contributed significantly to this research by providing the Anti-Human SNCA Therapeutic (SynO4) Antibody (Cat# TAB-0750CLV-L). This antibody was crucial for the experimental evaluation of the BTL's ability to reduce alpha-synuclein aggregation within neurons. By enabling the precise targeting and measurement of alpha-synuclein, the antibody from Creative Biolabs supported the validation of the therapeutic potential of BTL in mitigating the progression of Parkinson's disease.

Gravina, Alessia, et al. "Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression." Nature biotechnology 41.5 (2023): 717-727.

The study investigates the protection of cell therapeutics from antibody-mediated killing through the overexpression of CD64. This approach enhances the survival and efficacy of allogeneic cell therapeutics used in cancer therapy and regenerative medicine. The research demonstrates that engineered cells overexpressing CD64 can effectively evade antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are primary mechanisms of antibody-mediated rejection.
At Creative Biolabs, we provided several essential reagents for this research. These included the humanized anti-MICA IgG1 antibody (Cat#: TAB-0799CL), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0089WJ), the humanized anti-CD52 IgG1 antibody (Cat#: FAMAB-0014JF), and the hypusine antibody (Cat#: HPAB-0440-YJ). Our products were crucial for the experiments involving antibody-mediated killing assays, enabling the detailed examination of how engineered cells can evade immune detection and destruction. This study highlights the potential of CD64 overexpression to enhance the viability of cell-based therapies, underscoring our commitment to supporting advanced research and innovative therapeutic solutions.

Gravina, Alessia, et al. "Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity." Cell Stem Cell 30.11 (2023): 1538-1548.

This study investigates the development of synthetic immune checkpoint engagers to protect human leukocyte antigen (HLA)-deficient induced pluripotent stem cell-derived endothelial cells (iECs) from cytotoxic attacks by innate immune cells. By targeting specific immune receptors such as TIM3 and SIRPa, these synthetic molecules inhibit the cytotoxic actions of natural killer (NK) cells and macrophages. The aim is to create hypoimmune cells that can evade immune detection, enhancing the therapeutic potential of allogeneic cell therapies in immuno-oncology and regenerative medicine.
Creative Biolabs contributed significantly to this research by providing several key products. The humanized anti-MICA IgG1 antibody (Cat#: TAB-0799CL) and the humanized anti-SSEA-4 IgG1 antibody (Cat#: HPAB-N0258-YC) were crucial in conducting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays. These products enabled the researchers to assess the efficacy of the synthetic immune checkpoint engagers in protecting iECs from immune cell-mediated cytotoxicity, thus advancing the development of immune-evasive cell therapeutics.

Lu, Xinmiao, et al. "Radiolabeling and biological evaluation of 125 I-Necitumumab for EGFR-targeted SPECT imaging." Journal of Radioanalytical and Nuclear Chemistry 323 (2020): 83-89.

The study aimed to develop and evaluate a SPECT probe, 125I-Necitumumab, targeting the epidermal growth factor receptor (EGFR) for imaging non-small cell lung cancer (NSCLC). The researchers synthesized 125I-Necitumumab via the iodogen oxidation method and assessed its potential for SPECT imaging in vivo. The biodistribution study indicated rapid clearance of 125I-Necitumumab in most organs, with no significant uptake in tumor tissues despite the high EGFR expression. Consequently, the study concluded that 125I-Necitumumab is unsuitable for EGFR-targeted SPECT imaging of NSCLC.
Creative Biolabs provided the anti-human EGFR recombinant antibody Necitumumab (Cat#: TAB-119). The involvement of Creative Biolabs was crucial for obtaining the high-affinity EGFR-targeted antibody, enabling the researchers to synthesize the 125I-Necitumumab probe. This contribution facilitated the comprehensive evaluation of the probe's practicality for SPECT imaging, despite the final determination of its unsuitability for EGFR-targeted imaging in NSCLC.

Rasoulouniriana, Diana, et al. "T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors." Cancer Immunology Research 11.6 (2023): 792-809.

The study focused on engineering a modified FcgRI receptor for T cells, aiming to enhance their antibody-dependent cytotoxicity (ADCC) against solid tumors. This new receptor allows T cells to target tumor cells using antibodies, demonstrating effective and specific cytotoxicity only in the presence of appropriate antibodies. The engineered T cells, tested in both immunocompetent and immunodeficient mice, showed significant tumor eradication while secreting lower levels of cytokines compared to traditional CAR T cells, thus enhancing their safety profile. This technology offers a versatile approach, enabling the same engineered T cells to target different tumors by simply changing the injected antibody.
Creative Biolabs contributed by providing several critical antibodies for the study. Specifically, Creative Biolabs supplied Sofituzumab (Cat#: TAB-H63) and Necitumumab (Cat#: TAB-119). These antibodies were essential for testing the ADCC capabilities of the modified T cells, as they facilitated the targeting of specific tumor antigens, demonstrating the versatility and efficacy of the engineered T cells in preclinical models.

Solier, Stéphanie, et al. "A druggable copper-signalling pathway that drives inflammation." Nature 617.7960 (2023): 386-394.

This study focuses on the role of CD44-mediated copper uptake in regulating inflammation through metabolic and epigenetic reprogramming in macrophages. The researchers found that CD44 facilitates the uptake of copper(II) in mitochondria, which catalyzes NAD(H) redox cycling, promoting metabolic changes and subsequent epigenetic modifications that lead to an inflammatory state. They developed a metformin dimer, LCC-12, which inactivates mitochondrial copper(II), thereby inducing metabolic and epigenetic shifts that counteract macrophage activation. This study highlights the potential of targeting mitochondrial copper(II) as a therapeutic strategy to reduce inflammation in various disease models, including bacterial and viral infections.
Creative Biolabs contributed significantly to this research by providing the Anti-CD44 antibody (Cat# TAB-128CL). This antibody was crucial for the experiments involving the detection and analysis of CD44-mediated copper uptake in macrophages. The precise measurement and modulation of CD44 activity facilitated a deeper understanding of the mechanisms by which CD44 regulates macrophage metabolism and inflammation, thus supporting the study's exploration of new therapeutic approaches based on metabolic reprogramming.

Gomez, Karina E., et al. "Cancer cell CD44 mediates macrophage/monocyte-driven regulation of head and neck cancer stem cells." Cancer research 80.19 (2020): 4185-4198.

This study explores the interaction between tumor-associated macrophages (TAMs) and cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC), focusing on the role of the CD44 receptor. The researchers found that TAMs enhance the stemness and invasive properties of CSCs by modulating CD44 signaling pathways, particularly through the PI3K-4EBP1-SOX2 axis. Using patient-derived samples, in vitro coculture spheroid models, and in vivo mouse models, the study demonstrated that TAMs increase the availability of hyaluronic acid (HA), which binds to CD44 and activates signaling pathways that promote CSC growth and invasion. This mechanistic link between TAMs and CSCs provides insights into potential therapeutic targets for HNSCC.
Creative Biolabs provided essential reagents for this study, specifically the anti-CD44 monoclonal antibody (Cat# TAB-128CL). This antibody was crucial for the experiments involving CD44 detection and functional analysis in cancer cells. By enabling precise measurement and modulation of CD44 activity, the antibody facilitated a deeper understanding of how CD44 mediates the interaction between TAMs and CSCs. The use of Creative Biolabs' high-quality reagents significantly advanced the study's investigation into the molecular mechanisms underlying CSC regulation by TAMs.

Boreel, Daan F., et al. "Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models." Molecular Pharmaceutics 20.4 (2023): 2245-2255.

This study investigates the quantitative imaging of hypoxic CAIX-positive tumor areas with low immune cell infiltration in syngeneic mouse tumor models. The research focuses on developing a radiolabeled antibody targeting murine CAIX to visualize chronic hypoxia in these models and study the immune cell population in these hypoxic areas. Using the anti-mCAIX antibody (MSC3) conjugated to diethylenetriaminepentaacetic acid (DTPA) and radiolabeled with indium-111 ([111In]In-MSC3), the study demonstrated that this tracer specifically binds to CAIX-expressing cells in vitro and accumulates in CAIX-positive areas in vivo. The study highlighted that these CAIX-positive areas are characterized by reduced infiltration of immune cells, underscoring the immunosuppressive nature of chronic hypoxia in tumors. The findings suggest that this imaging technique can be used to optimize immuno- and radiotherapy efficacy by visualizing CAIX expression before or during hypoxia-targeted treatments.
Creative Biolabs provided the crucial human IgG1 anti-mouse CAIX antibody (Cat# TAB-1458CL) for this research. This antibody was pivotal in enabling the conjugation and radiolabeling processes necessary for developing the [111In]In-MSC3 tracer. By facilitating specific binding to CAIX-expressing cells and accumulation in hypoxic tumor regions, the MSC3 antibody allowed for the effective visualization and analysis of CAIX-positive hypoxic areas. This contribution was instrumental in advancing the study's objective of using CAIX as a biomarker for chronic hypoxia and its associated immunosuppressive microenvironment in preclinical models.

Tran Quang, Christine, et al. "Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia." Blood, The Journal of the American Society of Hematology 136.11 (2020): 1298-1302.

This study investigates the use of humanized, non-Fcg receptor-binding monoclonal antibodies (mAbs) targeting CD3 in the treatment of T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is a highly aggressive malignancy characterized by the proliferation of T-cell precursors. Traditional chemotherapy results in high cure rates in children but less success in adults. This study explores the antileukemic properties of humanized anti-CD3 mAbs, particularly hOKT3g1[Ala/Ala] and foralumab, in xenograft models of T-ALL. These antibodies demonstrated significant antileukemic activity, prolonged host survival, and cooperated with chemotherapy to enhance treatment efficacy, showing minor, manageable adverse effects.
Creative Biolabs provided essential antibodies for this study, including foralumab (Cat#: BPTG-061) and teplizumab (Cat#: TAB-159) as an alternative source of hOKT3γ1[Ala/Ala]. These antibodies, designed to prevent FcγR binding and reduce immune cell activation, were crucial in demonstrating the potent antileukemic activity in T-cell acute lymphoblastic leukemia (T-ALL) models. Their contribution enabled the researchers to validate the efficacy of non-FcγR-binding anti-CD3 antibodies in reducing leukemia burden and improving survival in xenograft models, thus supporting the potential of these engineered antibodies as a novel therapeutic strategy for T-ALL.

Laggner, Maria, et al. "The secretome of irradiated peripheral blood mononuclear cells attenuates activation of mast cells and basophils." EBioMedicine 81 (2022).

The study focused on the anti-allergic potential of the secretome of gamma-irradiated peripheral blood mononuclear cells (PBMCsec) in reducing the activation of mast cells and basophils, which are key players in allergic reactions. Researchers used both in vitro and in vivo models to investigate how PBMCsec influences mast cell degranulation and basophil activation, finding that PBMCsec effectively attenuates the activation of these immune cells. Specifically, topical application of PBMCsec on mouse ears significantly reduced tissue swelling caused by mast cell degranulation, while in vitro studies showed that PBMCsec inhibited mediator release from human dermal mast cells and basophils upon allergen stimulation. Transcriptomic analyses revealed that PBMCsec downregulates genes involved in immune cell activation and degranulation, underscoring its potential as an anti-allergic treatment.
Creative Biolabs provided the anti-human phosphatidylserine antibody Bavituximab (Cat#: TAB-175) used in this study. This antibody was essential for the blocking experiments that aimed to determine the role of phosphatidylserine (PS) in PBMCsec-mediated inhibition of basophil activation. The use of Bavituximab helped to elucidate the mechanisms by which PBMCsec prevents immune cell degranulation, thereby supporting the identification of PS and other lipid species as the active components responsible for the anti-allergic effects observed.

Reithofer, Manuel, et al. "4-1BB costimulation promotes bystander activation of human CD8 T cells." European Journal of Immunology 51.3 (2021): 721-733.

This study explores the impact of 4-1BB costimulation on human CD8 T cells, particularly focusing on bystander activation. The researchers used engineered antigen-presenting cells (eAPCs) expressing viral epitopes and costimulatory ligands to study how different costimulatory signals affect CD8 T cell responses. They found that while CD28 costimulation enhances antigen-specific CD8 T cell responses, 4-1BB costimulation, either through 4-1BB ligand (4-1BBL) or the agonist antibody urelumab, induces significant bystander proliferation of CD8 T cells and expansion of NK cells. This bystander activation is independent of the presented antigens and is characterized by increased cytokine production and cytotoxic activity.
Creative Biolabs contributed significantly to this research by providing the 4-1BB agonist antibody urelumab (Cat# TAB-179). This antibody was crucial for experiments investigating the effects of 4-1BB costimulation on CD8 T cells and NK cells. The use of urelumab enabled the researchers to demonstrate the unique ability of 4-1BB signals to promote bystander activation, thereby advancing the understanding of how 4-1BB costimulation can be harnessed in cancer immunotherapy while also highlighting potential off-target effects that need to be managed.

Upadhyaya, Punit, et al. "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist." Journal for immunotherapy of cancer 9.1 (2021).

This study investigates the development and efficacy of synthetic tumor-targeted CD137 agonists (TICAs) in inducing anticancer immunity. By using constrained bicyclic peptides (Bicycles) to create TICAs that link tumor antigens (like EphA2) with costimulatory receptors (such as CD137), the researchers were able to selectively activate these receptors in the presence of tumor cells. The study demonstrated that the EphA2/CD137 TICA (BCY12491) efficiently stimulated human peripheral blood mononuclear cells and resulted in significant tumor regression in mouse models. This approach highlights the potential of TICAs to provide effective and targeted cancer immunotherapy with a wide therapeutic index.
Creative Biolabs contributed to this research by supplying the anti-CD137 monoclonal antibody urelumab (Cat# TAB-179). This antibody was crucial for the experiments that investigated the effects of 4-1BB (CD137) costimulation on immune cells. The provision of this key reagent allowed researchers to demonstrate the unique capabilities of TICAs in promoting targeted tumor immunity, thereby supporting the development of new therapeutic strategies in cancer treatment.

Shorstova, Tatiana, et al. "Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP kinase inhibition." Molecular Cancer Therapeutics 20.1 (2021): 64-75.

This study investigates the synergy between epigenetic therapy using BET inhibitors (BETi) and MAP kinase inhibitors (MEKi) in treating small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), and other ovarian cancer subtypes. The researchers identified that combining the BET inhibitor OTX015 with MEK inhibitors cobimetinib and trametinib significantly represses the proliferation of SCCOHT both in vitro and in vivo. Mass spectrometry revealed that this combination therapy downregulates proteins involved in nucleotide metabolism, leading to reduced pools of nucleotide metabolites and subsequent cell-cycle arrest. This indicates that dual treatment with BETi and MEKi could be an effective therapeutic strategy against SCCOHT and other resistant ovarian cancers.
Creative Biolabs provided patritumab (anti-HER3 antibody, Cat# TAB-189), which was used to test the effects of targeting HER3 in combination with BETi in the ovarian cancer models. The inclusion of patritumab in the study was crucial for exploring the potential synergy between BET inhibitors and HER3 pathway inhibition. This helped to delineate the specificity and efficacy of the combined treatment strategies, thereby supporting the study's aim of identifying effective combination therapies for challenging ovarian cancer subtypes.

Wang, Liqin, et al. "cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis." Nature Cancer 3.11 (2022): 1284-1299.

This study investigates the effectiveness of combining cFLIP suppression and DR5 activation to target and eliminate senescent cancer cells. Utilizing CRISPR/Cas9-based genetic screens, researchers identified that senescent cells, which are resistant to apoptosis due to high cFLIP expression, can be sensitized to death by activating DR5 with an agonistic antibody. The study demonstrates that this combination treatment, enhanced by BRD2 inhibition, effectively kills senescent cells and induces a bystander effect, leading to the death of adjacent non-senescent cells in various cancer models.
Creative Biolabs significantly contributed to this research by supplying critical reagents. The agonistic antibody targeting DR5 (Cat#: TAB-203) and the BRD2 inhibitor provided by Creative Biolabs were instrumental in the study. These reagents enabled the researchers to validate the therapeutic strategy, demonstrating the potential of combining pro-senescence therapy with DR5 activation in cancer treatment.

Wiese, Teresa, et al. "Inhibition of acid sphingomyelinase increases regulatory T cells in humans." Brain Communications 3.2 (2021): fcab020.

This study investigated the impact of pharmacological inhibition of acid sphingomyelinase (ASM) on regulatory T cells (Tregs) in humans. The researchers aimed to determine whether ASM inhibitors could increase the frequency of Tregs among CD4+ T cells. The study utilized both in vitro experiments with human peripheral blood mononuclear cells (PBMCs) and an observational clinical trial with patients suffering from major depression. The results demonstrated that ASM inhibition with antidepressants like sertraline increased Treg frequencies in vitro and in patients treated with these antidepressants, indicating the potential of ASM inhibitors as immunomodulatory agents.
Creative Biolabs provided the anti-CTLA-4 monoclonal antibody, tremelimumab (Cat#: TAB-206), which was used to investigate the role of CTLA-4 in Treg frequency modulation. This antibody was crucial for determining that ASM inhibition increased Treg frequencies through enhanced CD28 co-stimulation. By blocking CTLA-4, the researchers were able to show that the increase in Treg frequencies required CD28 co-stimulation, highlighting the specific pathways through which ASM inhibitors affect Treg populations. The provision of tremelimumab enabled the detailed analysis of the mechanisms underlying Treg modulation in response to ASM inhibition, significantly contributing to the study's findings.

Calzetta, Luigino, et al. "Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab." British Journal of Pharmacology 177.20 (2020): 4750-4765.

This study investigates the effectiveness of targeting the IL-5 pathway in addressing airway hyperresponsiveness (AHR) in asthma by comparing two monoclonal antibodies, benralizumab and mepolizumab. The research focuses on their ability to modulate AHR in human airways passively sensitized to mimic asthmatic conditions. The study measures the inhibition of AHR to histamine, parasympathetic activation, and mechanical stress, as well as the modulation of cyclic AMP (cAMP) levels. The results demonstrate that both benralizumab and mepolizumab significantly reduce AHR, with benralizumab being more potent. The study concludes that targeting the IL-5/IL-5Rα axis is an effective strategy for preventing AHR.
Creative Biolabs provided the benralizumab (Cat# TAB-222) and mepolizumab (Cat# TAB-031) used in this study. These antibodies were essential for the comparative analysis of their effects on AHR and cAMP levels in human bronchial tissues. The use of these reagents allowed the researchers to determine the differential potency and efficacy of benralizumab and mepolizumab in modulating AHR, thus contributing significantly to the understanding of their therapeutic potential in treating asthma.

Tran Quang, Christine, et al. "Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia." Blood, The Journal of the American Society of Hematology 136.11 (2020): 1298-1302.

This study investigates the use of humanized, non-Fcg receptor-binding monoclonal antibodies (mAbs) targeting CD3 in the treatment of T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is a highly aggressive malignancy characterized by the proliferation of T-cell precursors. Traditional chemotherapy results in high cure rates in children but less success in adults. This study explores the antileukemic properties of humanized anti-CD3 mAbs, particularly hOKT3g1[Ala/Ala] and foralumab, in xenograft models of T-ALL. These antibodies demonstrated significant antileukemic activity, prolonged host survival, and cooperated with chemotherapy to enhance treatment efficacy, showing minor, manageable adverse effects.
Creative Biolabs provided essential antibodies for this study, including foralumab (Cat#: BPTG-061) and teplizumab (Cat#: TAB-159) as an alternative source of hOKT3γ1[Ala/Ala]. These antibodies, designed to prevent FcγR binding and reduce immune cell activation, were crucial in demonstrating the potent antileukemic activity in T-cell acute lymphoblastic leukemia (T-ALL) models. Their contribution enabled the researchers to validate the efficacy of non-FcγR-binding anti-CD3 antibodies in reducing leukemia burden and improving survival in xenograft models, thus supporting the potential of these engineered antibodies as a novel therapeutic strategy for T-ALL.

Cui, Guanglin, et al. "Preliminary functional and phylogeographic analyses of the 72 nucleotide duplication region in the emerging human respiratory syncytial virus ON1 strain attachment glycoprotein gene." Biomedicine & Pharmacotherapy 123 (2020): 109800.

This study investigates the emerging human respiratory syncytial virus (hRSV) ON1 strain, which is characterized by a 72-nucleotide duplication in the attachment glycoprotein (G) gene. The research utilized a pseudotype lentiviral system to examine the impact of this duplication on hRSV infection. The findings revealed that lentiviral pseudoparticles mimicked the essential functions of the G-protein in facilitating hRSV cell entry and that the deletion of the G-protein duplication significantly reduced the efficiency of pseudotyped lentiviral (pLV) infection. Additionally, the study performed Bayesian skyline and phylogeographic analyses on 199 ON1 sequences, providing insights into the evolutionary and geographical origins of the ON1 strain.
Creative Biolabs provided crucial monoclonal antibodies for this study. The anti-G monoclonal antibody 131-2G (CAT#: TAB-372CT) and the anti-F monoclonal antibody (CAT#: TAB-358CT) were used in Western immunoblotting to confirm the incorporation of G and F proteins into the pseudoparticles. Furthermore, the anti-G monoclonal antibody 131-2G (CAT#: TAB-372CT) was employed in antibody blockade experiments to demonstrate the role of the G protein in hRSV cell entry. These antibodies were essential for verifying the functionality of the pseudotyped lentiviral particles and for the subsequent functional analyses.

Li, Yumei, et al. "A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells." Translational Oncology 21 (2022): 101424.

This study explores the creation and efficacy of a novel multifunctional antibody, anti-PD-L1-CD16a-IL15, designed to target and kill PD-L1-overexpressing tumor cells. The researchers utilized recombinant human PD-L1-immunized llamas to develop anti-PD-L1 single-domain antibodies, which were then linked with anti-CD16a single-domain antibodies and the IL-15/IL-15Ra complex. This fusion protein, expressed and purified from HEK-293F cells, demonstrated significant in vitro and in vivo antitumor activity. It recruits T cells and activates NK cells to specifically target and kill PD-L1-positive tumor cells, showing enhanced efficacy over other antibody constructs in both cell cultures and xenograft models.
Creative Biolabs played a crucial role in this research by supplying several key reagents. Specifically, they provided the durvalumab antibody (Cat#: TAB-417CQ) used for comparison in cell proliferation assays and cytotoxicity studies. The comprehensive testing of anti-PD-L1-CD16a-IL15, including binding affinity, immune cell recruitment, and tumor inhibition, was facilitated by these high-quality reagents from Creative Biolabs. The products contributed to the study's ability to demonstrate the potential of anti-PD-L1-CD16a-IL15 as a potent cancer immunotherapy.

Kvorjak, Michael, et al. "Cross-talk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer." Cancer immunology research 8.2 (2020): 167-178.

The study investigated the interaction between colon cells and macrophages in the context of ulcerative colitis (UC) and colitis-associated colon cancer (CACC). Researchers found that macrophages, particularly the M2-like phenotype, play a significant role in promoting the expression of the glycosyltransferase ST6GALNAC1 in colon cancer cells. This enzyme catalyzes the addition of sialic acid to O-linked GalNAc residues, leading to the formation of tumor-associated sialyl-Tn (sTn) antigens on the mucin MUC1. The study demonstrated that the presence of M2 macrophages, through cytokines such as IL13 and CCL17, increased the expression of ST6GALNAC1 and the corresponding MUC1-sTn glycoform, contributing to the pathogenesis and progression of UC and CACC.
Creative Biolabs provided the anti-MUC1 antibody 5E5 (Cat#: TAB-418MZ) used in the study. This antibody was crucial for identifying and quantifying the MUC1-sTn glycoform in tissue samples and cell cultures. By enabling the detection of specific glycoforms of MUC1, the antibody facilitated the evaluation of macrophage-induced changes in glycosylation patterns, thus playing a vital role in elucidating the mechanisms through which macrophages influence colon cancer progression.

Battin, Claire, et al. "NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E." Immunology 166.4 (2022): 507-521.

This study investigates the dependence of NKG2A-checkpoint inhibition and its blockade on peptides presented by its ligand HLA-E. Researchers evaluated how different HLA-E-bound peptides impact the inhibitory signaling of NKG2A and the efficacy of monalizumab, a novel immune checkpoint inhibitor (ICI) targeting NKG2A. They found that various peptides derived from the leader sequences of classical MHC class I molecules and the non-classical class I paralogue HLA-G mediate different levels of NKG2A inhibition. The study shows that monalizumab's effectiveness in enhancing NK and CD8+ T cell responses depends significantly on the specific peptide presented by HLA-E, with peptides from HLA-G being less effectively blocked compared to those from HLA-A, HLA-B, and HLA-C.
At Creative Biolabs, we contributed to this critical research by supplying the therapeutic NKG2A antibody monalizumab (Cat#: TAB-437CQ) used in the study to assess its binding and blocking capacities. Our product was essential in demonstrating that monalizumab's efficiency in blocking NKG2A-mediated inhibition varies with different HLA-E-bound peptides. This research highlights the importance of peptide-HLA-E interactions in determining the success of NKG2A-targeted immunotherapies, showcasing our commitment to advancing cancer immunotherapy research and developing innovative therapeutic solutions.

Choi, Seong Jin, et al. "KIR+ CD8+ and NKG2A+ CD8+ T cells are distinct innate-like populations in humans." Cell Reports 42.3 (2023).

This study explores the heterogeneity among human KIR+CD8+ and NKG2A+CD8+ T cells, identifying them as distinct innate-like populations with different cytokine responsiveness. The research demonstrates that KIR+CD8+ T cells exhibit IL-15-induced NK-like cytotoxicity, while NKG2A+CD8+ T cells show IL-12/IL-18-induced IFN-gamma production. It was observed that KIR+CD8+ T cells are more terminally differentiated and replicative senescent compared to NKG2A+CD8+ T cells, which are more responsive to IL-12 and IL-18 due to the high expression of these receptors induced by the transcription factor PLZF.
At Creative Biolabs, we provided essential reagents for this study, including the anti-NKG2A antibody (Cat#: TAB-437CQ) and the IgG4 isotype control (Cat# MOB-0408ZL) used in the flow cytometry analyses. Our products were crucial in identifying the distinct functional roles and cytokine responses of these T cell subsets. This research underscores the importance of understanding the diverse functions of T cell populations in developing targeted immunotherapies, highlighting our commitment to advancing immunological research and innovative therapeutic solutions.

Hirsch, Theo Z., et al. "Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer." Cancer discovery 11.10 (2021): 2524-2543.

The study conducted an integrated genomic analysis of 126 pediatric liver tumors to uncover driver genes and mechanisms associated with cisplatin resistance. The research identified significant molecular heterogeneity in hepatoblastoma subtypes, revealing plasticity between different molecular subgroups such as "hepatocytic," "liver progenitor," and "mesenchymal." The study found that chemotherapy induces a specific mutational signature in "liver progenitor" cells, leading to heavily mutated relapses and metastases. Additionally, the research validated potential therapeutic targets for cisplatin-resistant progenitor cells through drug screening and mouse xenograft experiments.
Creative Biolabs provided the monoclonal human anti-IGF1/IGF2 therapeutic antibody, Xentuzumab (Cat#: TAB-475CQ), which played a critical role in the study's investigation of new therapeutic strategies for pediatric liver cancer. The antibody was tested at a final concentration of 1 μmol/L, resuspended in PBS at 1 mg/mL, to evaluate its efficacy in inhibiting tumor growth. The provision of Xentuzumab by Creative Biolabs was essential in validating its potential as a targeted treatment, particularly for cisplatin-resistant progenitor cells, thereby contributing significantly to the exploration of alternative therapies for this aggressive form of cancer.

Wei, Yun, et al. "Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma." Nature cancer 3.8 (2022): 961-975.

This study investigates the conservation of cellular hierarchy and the identification of tumor-propagating cells (TPCs) in rhabdomyosarcoma (RMS) using single-cell RNA sequencing, DNA-barcode cell fate mapping, and functional stem cell assays. The research uncovers shared tumor cell hierarchies in RMS and human muscle development, identifying common developmental stages where tumor cells become arrested. It highlights the molecularly-defined TPCs in fusion-negative RMS (FN-RMS) that resemble early myogenic cells found in embryonic and fetal development. These TPCs are quiescent under normal conditions but can re-enter the cell cycle to drive tumor growth under stress or in vivo conditions.
Creative Biolabs provided crucial reagents for this study, specifically the anti-LRRN1 antibody (Cat# TAB-522MZ). These antibodies were essential for the fluorescence-activated cell sorting (FACS) used to isolate mesenchymal-like and differentiated muscle cell populations. By enabling the identification and enrichment of specific cell states within FN-RMS, these reagents facilitated the detailed characterization of TPCs and their role in tumor growth and maintenance, supporting the study's exploration of cellular hierarchies in RMS.

Desjardins, Cody A., et al. "Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice." Nucleic acids research 50.20 (2022): 11401-11414.

This study focuses on developing an enhanced delivery mechanism for phosphorodiamidate morpholino oligomers (PMO) to treat Duchenne muscular dystrophy (DMD). Traditional therapies aim to induce exon skipping in the dystrophin pre-mRNA to produce a functional dystrophin protein. However, these therapies often face challenges in effectively delivering PMO to cardiac and skeletal muscles. To address this, the researchers developed the FORCE™ platform, which utilizes a Fab fragment targeting the transferrin receptor 1 (TfR1) conjugated to the PMO. This approach demonstrated significantly improved muscle delivery, achieving dose-dependent and robust exon skipping and sustained dystrophin restoration in mdx mice, a model for DMD.
Creative Biolabs provided several key products for this study, significantly contributing to its success. They supplied the human monoclonal antibody targeting human TfR1 (15G11, Cat# TAB-611CT), which was essential for validating the specificity and efficacy of the FORCE™ conjugate. Additionally, Creative Biolabs provided other critical reagents and antibodies that facilitated the extensive biochemical and molecular analyses conducted in the study. These contributions were crucial in enabling the detailed examination of the FORCE™ platform's ability to enhance PMO delivery and restore dystrophin expression, thereby demonstrating its potential as an effective treatment approach for DMD.

Tang, Wei, et al. "Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in respiratory syncytial virus fusion protein." Journal of Virology 95.20 (2021): 10-1128.

This study investigates the mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in the respiratory syncytial virus (RSV) fusion protein. The researchers employed a dual-luciferase protocol to discover LF-6, a small-molecule inhibitor that targets the RSV fusion glycoprotein. They found that the K394R mutation not only conferred resistance to LF-6 but also to other RSV fusion inhibitors, including those in clinical development. This mutation destabilizes the F protein and enhances its membrane fusion activity, increasing viral resistance. The study highlights the need for alternative strategies to combat RSV infections, given the resistance risks posed by the K394R mutation.
In this research, Creative Biolabs provided crucial reagents that facilitated the experiments. Specifically, the D25 monoclonal antibody (Cat# PABL-322) and Motavizumab (Cat# TAB-709) were used for detecting RSV F protein in various assays, including the immunofluorescence and cell-surface triggering assays. These antibodies were essential for accurately identifying the effects of mutations on the RSV F protein and assessing the resistance mechanisms. The products from Creative Biolabs significantly contributed to the detailed analysis and validation of the findings related to the K394R mutation and its impact on RSV fusion inhibitor resistance.

Bender, Andrew T., et al. "TLR7 and TLR8 differentially activate the IRF and NF-κB pathways in specific cell types to promote inflammation." Immunohorizons 4.2 (2020): 93-107.

This study investigates how TLR7 and TLR8 differentially activate the IRF and NF-κB pathways in specific cell types to promote inflammation. TLR7 and TLR8 are endosomal receptors that recognize single-stranded RNA (ssRNA) and play critical roles in antiviral defense and the pathogenesis of autoimmune diseases such as lupus. The research uses cell sorting, gene expression analysis, and intracellular cytokine staining to characterize the effects of TLR7 and TLR8 activation in various human immune cells. The study found that TLR7 primarily activates the IRF pathway leading to type I IFN production, while TLR8 predominantly activates the NF-κB pathway, resulting in the production of inflammatory cytokines. These findings enhance the understanding of the distinct roles TLR7 and TLR8 play in immune responses and their contributions to autoimmune diseases.
Creative Biolabs provided the anti-IFNAR antibody anifrolumab (Cat#: TAB-722) used in this study. Anifrolumab was crucial in experiments designed to block type I IFN activity, allowing researchers to differentiate between gene expression changes directly induced by TLR7/8 activation and those mediated by secondary IFN responses. The antibody was pivotal in demonstrating that inhibiting IFN activity can prevent secondary IFN-induced gene expression while not affecting NF-κB-regulated genes directly induced by TLR7/8 activation. This contribution was essential for elucidating the distinct pathways and effects mediated by TLR7 and TLR8 activation in various cell types.

Zheng, Jian, et al. "Severe acute respiratory syndrome coronavirus 2-induced immune activation and death of monocyte-derived human macrophages and dendritic cells." The Journal of infectious diseases 223.5 (2021): 785-795.

This study examines the infection and immune response of human monocyte-derived macrophages (MDMs) and dendritic cells (MDDCs) by SARS-CoV-2. The research found that although SARS-CoV-2 infects these cells abortively, it still induces the production of multiple proinflammatory cytokines and chemokines, such as IFN-α, IFN-β, TNF, IL-1β, IL-6, IL-8, IL-10, and CXCL10. This infection triggers a type I IFN-mediated cell death, contributing to the inflammatory response observed in COVID-19. The study also demonstrated that infection is dependent on the ACE2 receptor and that the presence of convalescent plasma can block this infection without enhancing macrophage cell death, suggesting the non-involvement of antibody-dependent enhancement in cell death.
Creative Biolabs provided the IFN-α receptor (IFNAR) monoclonal antibody Anifrolumab (Cat#: TAB-722) used to block type I IFN signaling in this study. The antibody was crucial in demonstrating that blocking IFNAR reduced the percentage of cell death in SARS-CoV-2-infected MDMs. This blocking assay helped to reveal the role of type I IFNs in mediating the apoptosis of MDMs post-infection, thereby offering insights into the mechanisms of macrophage activation and cell death during SARS-CoV-2 infection.

Gong, Ke, et al. "EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer." Nature cancer 1.4 (2020): 394-409.

This study explores the impact of EGFR inhibition on type I interferon (IFN) signaling in non-small cell lung cancer (NSCLC). Researchers found that inhibiting EGFR in NSCLC triggers an antiviral defense mechanism, resulting in the upregulation of type I IFNs via the RIG-I-TRIM32-TBK1-IRF3 pathway in EGFR-mutant cells, and via an NF-κB-dependent pathway in EGFR wild-type (EGFRwt) cells. The study demonstrates that the upregulation of type I IFNs contributes to both primary and secondary resistance to EGFR-tyrosine kinase inhibitors (TKIs). Additionally, the study suggests that combining EGFR-TKI treatment with IFN signaling inhibition could improve treatment efficacy and overcome resistance in both EGFR-mutant and EGFRwt NSCLC.
Creative Biolabs provided the anifrolumab antibody (Cat#: TAB-722) used in this study. Anifrolumab was crucial for experiments involving the inhibition of type I IFN signaling. The use of anifrolumab allowed researchers to demonstrate that blocking IFNAR enhances the sensitivity of NSCLC cells to EGFR inhibition, thereby reducing cell survival and preventing the development of resistance to EGFR-TKIs. This antibody was essential in illustrating the potential therapeutic benefit of combining EGFR-TKIs with IFN signaling inhibitors to improve treatment outcomes in NSCLC.

Chew, Hui Yi, et al. "Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies." Cell 180.5 (2020): 895-914.

This study explores the use of prochlorperazine (PCZ) to inhibit endocytosis in vivo and enhance the efficacy of therapeutic antibodies targeting cancers. The researchers conducted both preclinical and clinical studies to evaluate the potential of PCZ to block endocytosis temporarily, thereby increasing the availability and effectiveness of antibodies such as cetuximab and trastuzumab on the surface of tumor cells. The study demonstrated that PCZ treatment could significantly enhance antibody-dependent cellular cytotoxicity (ADCC) and improve the therapeutic outcomes in head and neck squamous cell carcinoma (HNSCC) models.
Creative Biolabs provided humanized monoclonal antibodies for this study, specifically targeting HER3 and IGF-1R. The products included lumretuzumab (Cat# TAB-H47) and dalotuzumab (Cat# TAB-736). These antibodies were used at a final concentration of 60 μg/mL for immunofluorescence and ADCC assays. Lumretuzumab and dalotuzumab played a critical role in the study's examination of antibody internalization and antibody-dependent cellular cytotoxicity (ADCC) in various cancer cell lines, allowing researchers to assess the therapeutic potential and efficacy of these targeted treatments.

Jiao, Rubin, et al. "A Theranostic Approach to Imaging and Treating Melanoma with 203Pb/212Pb-Labeled Antibody Targeting Melanin." Cancers 15.15 (2023): 3856.

This study investigates a theranostic approach to imaging and treating melanoma by targeting melanin with radiolabeled antibodies. The researchers used a chimeric antibody, c8C3, labeled with two isotopes of lead: Lead-203 for SPECT imaging and Lead-212 for radioimmunotherapy. The study demonstrated that 203Pb-labeled c8C3 enabled effective imaging of melanoma tumors in mice, while 212Pb-labeled c8C3 significantly slowed tumor growth and improved survival rates without causing hematologic or systemic toxicity. This approach highlights the potential of using radiolabeled antibodies for both diagnostic and therapeutic purposes in melanoma treatment.
Creative Biolabs provided the humanized anti-CD33 antibody lintuzumab (Cat# TAB-756) used as a negative control in this study. This antibody was crucial for validating the specificity and effectiveness of the melanin-targeting c8C3 antibody. The reliable performance of the lintuzumab antibody from Creative Biolabs ensured accurate control experiments, thereby supporting the overall conclusions regarding the therapeutic potential of the melanin-targeting radiolabeled antibodies.

Candiello, Ermes, et al. "MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis." Molecular Oncology 17.7 (2023): 1280-1301.

The study investigated the role of microRNA 483-3p (miRNA-483-3p) in metastatic colorectal cancer, focusing on its impact on cancer aggressiveness and invasion. Researchers found that overexpression of miRNA-483-3p increased the proliferation, invasiveness, and stem-like properties of cancer cells by downregulating NDRG1, a metastasis suppressor gene. This downregulation led to the activation of the ERBB3/AKT signaling pathway, which is associated with epithelial-mesenchymal transition (EMT) and cancer progression. The study utilized various experimental approaches, including patient-derived xenografts, m-colosphere cultures, and transcriptomic analyses, to demonstrate the mechanistic link between miRNA-483-3p, NDRG1, and ERBB3/AKT signaling in colorectal cancer.
Creative Biolabs provided the anti-ERBB3 antibody seribantumab (Cat#: TAB-892) used in this study. This antibody was critical for evaluating the role of ERBB3 in miRNA-483-3p-mediated cancer cell invasion and growth. Treatment with MM121 effectively counteracted the invasive growth induced by miRNA-483-3p overexpression, highlighting its potential as a therapeutic agent for targeting ERBB3 in colorectal cancer. The provision of MM121 by Creative Biolabs enabled the researchers to validate the functional significance of ERBB3 activation in the context of miRNA-483-3p overexpression, contributing to the overall findings of the study.

Bill, Marius, et al. "EGFL7 antagonizes NOTCH signaling and represents a novel therapeutic target in acute myeloid leukemia." Clinical Cancer Research 26.3 (2020): 669-678.

This study investigated the role of EGF-like domain 7 (EGFL7) in acute myeloid leukemia (AML) and its potential as a therapeutic target. The researchers found that EGFL7 is upregulated in AML and contributes to leukemogenesis by antagonizing NOTCH signaling. Through various in vitro and in vivo experiments, the study demonstrated that blocking EGFL7 with an anti-EGFL7 antibody (parsatuzumab) reactivated NOTCH signaling, leading to increased differentiation and apoptosis of leukemic cells. Additionally, anti-EGFL7 treatment prolonged the survival of AML mouse models, indicating the potential of EGFL7 as a novel therapeutic target for AML.
Creative Biolabs provided the anti-EGFL7 therapeutic antibody, parsatuzumab (Cat#: TAB-902), which was critical for the experiments that demonstrated the reactivation of NOTCH signaling and the resulting differentiation and apoptosis of AML cells. The use of parsatuzumab allowed the researchers to validate the therapeutic potential of targeting EGFL7 in AML and provided significant insights into the molecular mechanisms by which EGFL7 influences leukemogenesis. This contribution was essential for establishing EGFL7 as a viable target for AML treatment.

Bill, Marius, et al. "EGFL7 antagonizes NOTCH signaling and represents a novel therapeutic target in acute myeloid leukemia." Clinical Cancer Research 26.3 (2020): 669-678.

This study examined the prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia (AML). Researchers found that EGFL7 is overexpressed in AML blasts compared to normal bone marrow cells, and higher EGFL7 expression is associated with lower complete remission rates and shorter event-free and overall survival. EGFL7 promotes AML blast growth through an autocrine mechanism by enhancing cell proliferation and survival. In vitro experiments demonstrated that EGFL7 blockade with an anti-EGFL7 antibody reduced the growth and viability of AML cells, highlighting its potential as a therapeutic target.
Creative Biolabs provided the critical anti-EGFL7 monoclonal antibody parsatuzumab (Cat#: TAB-902). This antibody was crucial for blocking EGFL7 function, which allowed the researchers to observe decreased proliferation and increased apoptosis of AML cells. The use of this antibody enabled the validation of EGFL7 as a therapeutic target and significantly contributed to understanding the mechanisms through which EGFL7 influences leukemic cell growth and survival.

Chew, Hui Yi, et al. "Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies." Cell 180.5 (2020): 895-914.

This study explores the use of prochlorperazine (PCZ) to inhibit endocytosis in vivo and enhance the efficacy of therapeutic antibodies targeting cancers. The researchers conducted both preclinical and clinical studies to evaluate the potential of PCZ to block endocytosis temporarily, thereby increasing the availability and effectiveness of antibodies such as cetuximab and trastuzumab on the surface of tumor cells. The study demonstrated that PCZ treatment could significantly enhance antibody-dependent cellular cytotoxicity (ADCC) and improve the therapeutic outcomes in head and neck squamous cell carcinoma (HNSCC) models.
Creative Biolabs provided humanized monoclonal antibodies for this study, specifically targeting HER3 and IGF-1R. The products included lumretuzumab (Cat# TAB-H47) and dalotuzumab (Cat# TAB-736). These antibodies were used at a final concentration of 60 μg/mL for immunofluorescence and ADCC assays. Lumretuzumab and dalotuzumab played a critical role in the study's examination of antibody internalization and antibody-dependent cellular cytotoxicity (ADCC) in various cancer cell lines, allowing researchers to assess the therapeutic potential and efficacy of these targeted treatments.

Meyer, Mickael, et al. "Profiling the non-genetic origins of cancer drug resistance with a single-cell functional genomics approach using predictive cell dynamics." Cell systems 11.4 (2020): 367-374.

This study investigates the non-genetic origins of cancer drug resistance through a novel method called fate-seq. Fate-seq links the drug response of single cells to their transcriptomic profiles, enabling the identification of molecular factors that contribute to intrinsic drug resistance. The researchers focused on HeLa cells treated with tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) as a proof of concept. The study demonstrated that cell dynamics could distinguish transient transcriptional states, leading to a better understanding of why some cells survive cancer treatments while others do not.
Creative Biolabs provided critical reagents that were instrumental in validating the research findings. Specifically, the therapeutic antibody mapatumumab (cat# TAB-H48) was supplied by Creative Biolabs, which played a crucial role in demonstrating the increased sensitivity of cells overexpressing SIVA1 to death receptor-mediated apoptosis. This contribution was significant as it helped confirm the potential of SIVA1 as a target gene for enhancing TRAIL-induced cell death.

Wiese, Teresa. Pharmacological targeting of acid sphingomyelinase increases CD4\(^+\) Foxp3\(^+\) regulatory T cell subsets in patients with major depression. Diss. Universität Würzburg, 2022.

The study investigates the pharmacological inhibition of acid sphingomyelinase (ASM) and its effects on human T cells, both in vitro and in vivo. The research aimed to analyze how inhibiting ASM affects the immune response, particularly focusing on the role of CD4+ Foxp3+ regulatory T cells (Tregs). By understanding the sphingolipid metabolism in these cells, the study explores how changes in sphingolipid content and functionality can influence immune cell behavior, which has implications for treating autoimmune and inflammatory diseases, as well as viral infections .
Creative Biolabs significantly contributed to this research by providing essential reagents. They supplied the PD-1 inhibiting monoclonal antibody pembrolizumab and the CTLA-4 inhibiting monoclonal antibody tremelimumab (CAT#: TAB-H55). These reagents were crucial for the experiments involving the modulation of immune responses, allowing the researchers to study the effects of blocking specific immune checkpoints. The use of these antibodies enabled detailed examination of the underlying mechanisms affected by ASM inhibition, thus advancing the understanding of T cell regulation and the potential therapeutic applications .

Rasoulouniriana, Diana, et al. "T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors." Cancer Immunology Research 11.6 (2023): 792-809.

The study focused on engineering a modified FcgRI receptor for T cells, aiming to enhance their antibody-dependent cytotoxicity (ADCC) against solid tumors. This new receptor allows T cells to target tumor cells using antibodies, demonstrating effective and specific cytotoxicity only in the presence of appropriate antibodies. The engineered T cells, tested in both immunocompetent and immunodeficient mice, showed significant tumor eradication while secreting lower levels of cytokines compared to traditional CAR T cells, thus enhancing their safety profile. This technology offers a versatile approach, enabling the same engineered T cells to target different tumors by simply changing the injected antibody.
Creative Biolabs contributed by providing several critical antibodies for the study. Specifically, Creative Biolabs supplied Sofituzumab (Cat#: TAB-H63) and Necitumumab (Cat#: TAB-119). These antibodies were essential for testing the ADCC capabilities of the modified T cells, as they facilitated the targeting of specific tumor antigens, demonstrating the versatility and efficacy of the engineered T cells in preclinical models.

Shiomi, Mayu, et al. "CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer." Cancer Science 112.9 (2021): 3655-3668.

This study focused on evaluating the cytotoxic effects of a CD70 antibody-drug conjugate (CD70-ADC) on ovarian cancer cells both in vitro and in vivo. The researchers assessed CD70 expression in ovarian cancer cell lines and clinical samples. They found that CD70 expression was significantly higher in ovarian cancer cells exposed to cisplatin, particularly in those with resistance to the drug. The CD70-ADC was developed using an anti-CD70 monoclonal antibody linked to monomethyl auristatin F (MMAF). The study demonstrated that CD70-ADC had a substantial inhibitory effect on the growth of CD70-expressing ovarian cancer cells, suggesting its potential as a novel therapeutic agent for treating ovarian cancer.
Creative Biolabs played a crucial role in this research by providing the anti-CD70 monoclonal antibody, vorsetuzumab (Cat#: TAB-H76), which was essential for creating the CD70-ADC. This antibody was conjugated with MMAF to produce the CD70-ADC used in the experiments. The specific anti-CD70 antibody provided by Creative Biolabs was vital for targeting CD70-expressing ovarian cancer cells and demonstrating the therapeutic potential of CD70-ADC in inhibiting tumor growth in both in vitro and in vivo models. The provision of this high-quality monoclonal antibody enabled the researchers to effectively explore the cytotoxic effects and therapeutic implications of CD70-ADC in ovarian cancer treatment.

Chen, Haizhang, et al. "Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel." EMBO Molecular Medicine 14.1 (2022): e14182.

This study focuses on developing a robust and scalable test system to detect and quantify the bioactivity of soluble IgG immune complexes (sICs). These complexes play a significant role in autoimmune diseases such as systemic lupus erythematosus (SLE). The researchers created a comprehensive panel of reporter cell lines that enable the quantification of sIC reactivity through ELISA or flow cytometry. This system identified FcγRIIA(H) and FcγRIIIA as the most sensitive receptors to sICs, allowing for the detailed analysis of sIC size and stoichiometry. The assay has shown predictive capabilities regarding the severity of SLE by analyzing sera from patients and mouse models, providing a sensitive tool to evaluate sICs in various settings.
Creative Biolabs contributed to this study by providing the pharmaceutical-grade humanized monoclonal IgG1 antibody rituximab (Cat# TP-082CL). Rituximab was crucial for generating soluble immune complexes (sICs) in the experiments. The study utilized recombinant CD20, obtained as a peptide containing the binding region of rituximab, to form these sICs. This setup allowed the researchers to create and analyze the immune complexes accurately. The high-quality rituximab provided by Creative Biolabs enabled the development of a sensitive and specific assay for detecting Fcγ receptor activation, which was essential for the study's success in evaluating the bioactivity and size of sICs.

More Infomation

CAT	Product Name	Application	Type
MOB-0402ZL	Human IgG1, kappa - Isotype Control Antibody	ELISA
MRO-523-PMZ	Anti-Bacterial alkaline phosphatase Polyclonal Antibody (HRP)	ELISA	Rabbit antibody
MRO-623-RMZ	Recombinant Anti-P. aeruginosa Antibody (B11)	ELISA	Mouse antibody
MRO-776-RMZ	Recombinant Anti-Streptococcus equi subsp. equi Antibody (MAB212P)	ELISA	Mouse antibody

CAT	Product Name	Application	Type
PABX-171	Recombinant Mouse Anti-Shigella flexneri variant Y Antibody (SYA/J6)	WB, ELISA, FuncS	IgG
PABX-171-S (P)	Recombinant Mouse Anti-Shigella flexneri variant Y Antibody scFv Fragment (SYA/J6)	WB, ELISA, FuncS	scFv
PABX-171-F (E)	Recombinant Mouse Anti-Shigella flexneri variant Y Antibody Fab Fragment (SYA/J6)	WB, ELISA, FuncS	Fab

CAT	Product Name	Application	Type
MHC-LC3377	PE-B*14:02/Human (DRYRRIHSL) MHC Tetramer	FCM

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Anti-C. difficile cell surface protein Polyclonal Antibody (CAT#: MRO-075-PMZ)

Specifications

Related Resources

Product Notes

Downloads

See other products

Customer Reviews and Q&As

Popular products with customers